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ABSTRACT 
Breast cancer remains one of the leading causes of cancer death in women with 
one in eight women expected to develop breast cancer.  Breast cancer progression causes 
several adverse changes in the extracellular matrix (ECM) composition and organization 
including an increase in stromal collagen and stiffening of the ECM.  Clinical studies 
have recently discovered that stiff and dense breast tissue, a result of the abnormal 
architecture of the tumor microenvironment, correlates with breast tumor growth and 
increases the likelihood of tumor metastasis.  However, the tumor microenvironment 
influence on cancer progression and intracellular behavior is not well understood due to 
the lack of physiologically relevant three dimensional (3D) in vitro models that are able 
to capture the mechanical and structural in vivo complexity and are also able to provide 
rigorous and quantitative understanding.  The goal of this dissertation is to investigate 
how the mechanical components of the microenvironment influence intracellular and 
molecular activity to drive cancer progression in a robust and scalable 3D system.   
 In order to address these gaps, our work studied the the impact of collagen 
concentration, cell type, and drug incubation time on drug response in 2D and 3D 
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environments.  To understand the role of local cellular mechanics in mediating drug 
response, we optimized and utilized particle-tracking microrheology to quantify the 
intracellular activity of single cells and spheroids embedded in 3D collagen gels.  Finally, 
our study connected both structure and mechanics with cell signaling by investigating the 
relationship between the mechanical components of the ECM and the YAP/TAZ 
pathway. Furthermore, we integrated our 3D embedded spheroid model with tissue 
clearing methods to allow for complete visualization of YAP/YAZ activity throughout 
the dense spheroid structure.   
Collectively, the results showed that matrix properties interact with matrix 
dimensionality to influence drug response.  This interaction also was found to affect 
intracellular activity, even in the presence of chemotherapeutic and anti-MMP drugs.  We 
then showed how this interaction in mechanics and ECM properties affects the spatial 
and temporal heterogeneity of YAP/YAZ activity within a 3D spheroid.  Overall, the 
work in this dissertation provides new insights into how the physical properties of the 
tumor microenvironment influence cellular form and function, as well as response to 
therapy of cancer cells, which may have implications on development of novel treatment 
strategies and patient outcome.  
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CHAPTER 1. Introduction 
Mechanical forces play a critical role in many biological processes including 
morphogenesis, cell division, and migration2.  The mechanical behavior of cells is 
affected by the heterogeneous cytoplasm and the forces propagated through the ECM.  
Cells obtain signals from the extracellular microenvironment and accordingly adjust their 
intracellular mechanical properties3,4.  Tensional homeostasis, the equilibrium of 
extracellular and intracellular forces, is regulated by cells and tissues continuously 
adjusting tensional forces5.  
 When tensional homeostasis is disrupted due to disease or inflammation, the cell 
and tissue behavior becomes unbalanced, which can lead to undesirable outcomes6,7.  In 
the case of breast cancer, tumors become several times stiffer than the surrounding 
normal tissue8,9.  The ECM is affected by changes in the mechanical properties of cancer 
cells, which leads to an increase in collagen deposition and reorganization of matrix 
proteins10,11.  Clinical studies have recently found that stiffer and denser breast tissue 
leads to increased metastasis and tumor growth12,13.  However, the tumor 
microenvironment influence on cancer progression and intracellular behavior is not well 
understood due to the lack of physiologically relevant three-dimensional in vitro models 
that are able to capture the mechanical complexity of physiological environments and 
provide quantitative analysis.  Therefore, there is a need to understand how changes in 
the ECM stiffness alter cellular behavior in order to develop improved treatment 
strategies for breast cancer.   
 Previous studies have not quantitatively characterized the interaction between the 
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ECM and intracellular mechanics or drug response of cells within a 3D matrix due to lack 
of non-disruptive 3D analysis techniques and representative in vitro models7,14,15.  In 
addition, cells are commonly cultured on 2D plastic or glass substrates, which drastically 
alters the morphology and mechanical behavior of cells from their natural in vivo 
environment16,17.  Consequently, the extracellular factors that cause a varied drug 
response in cancerous cells is not well understood.   
The YAP/TAZ pathway is linked to the structural and mechanical components of 
the microenvironment.  Accordingly, mechanical inputs such as matrix stiffness and cell 
morphology directly regulate YAP and TAZ activity.  In addition, elevated expression of 
YAP/TAZ has been found to correlate with increased metastasis and chemoresistance.  
However, the influence of the mechanical properties of the matrix on YAP/TAZ activity 
has not been investigated within a physiologically relevant 3D system. 
 As a result, there are several gaps in knowledge in cellular mechanics and the 
tumor microenvironment including unclear characterization of the relationship between 
intracellular activity and the tumor microenvironment in 3D.   In addition, the lack of 
robust native like models leads to inaccurate translation of information from 2D studies 
to an in vivo cellular response.  Furthermore, the mechano-sensitive YAP/TAZ signaling 
pathway, though shown to influence ECM mechanics and be correlated with malignant 
cancers18,19, has not been thoroughly investigated within a 3D system.  Due to these gaps 
in knowledge, we proposed three aims to investigate our central question:  How does the 
tumor microenvironment impact intracellular properties within a 3D system?  
! 3 
1.1 Hypothesis and Main Questions 
Based on our work and current literature, we hypothesized that the mechanical 
components of the tumor microenvironment impact the intracellular activity and 
molecular signaling of cells to influence cancer progression.  The goal of this work was 
to develop and refine novel methods to understand the relationship between the 
mechanical components of the microenvironment and intracellular behavior.  The overall 
scope of this thesis was to answer 3 specific aims.   
 
Aim 1: Investigation of the impact of the microenvironment and drug incubation time on 
drug response 
 Conventional drug studies use cells cultured on polystyrene or glass substrates 
and apply these results to predict outcomes for in vivo conditions.  Though the 2D in vitro 
model is fast and cost effective, results from these conditions often fail to recapitulate in 
vivo behavior.  These 2D models do not incorporate key cell-ECM interactions found in 
vivo and force cells to assume an unnatural morphology.  The work described in this aim 
investigates a more physiologically relevant in vitro model composed of single cells 
embedded within a 3D collagen gel.  The drug response within a conventional 2D model 
and 3D single cell embedded model are compared and the influence of drug incubation 
time, 3D collagen concentration, and cell type on drug response are studied.  
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Aim 2: Study of microenvironment impact on mechanical behavior of cells in an in vitro 
3D model 
 The ECM composition and organization changes drastically with breast cancer 
progression including stiffening of the ECM and increase in stromal collagen.  The tumor 
microenvironment has also been shown to influence and be influenced by the mechanical 
behavior of cells.  However, the relationship between stiff and dense breast tissue in 
patients and increased breast tumor growth and metastasis is not well characterized.  To 
understand how the matrix mechanics impacts the intracellular activity of cells, we 
utilized particle-tracking microrheology.  This approach allows for the quantification of 
intracellular mechanics and active force fluctuations for cells embedded inside a 3D 
environment without disturbing the cell or the matrix.  In addition, the cellular response 
to drug treatments can be studied with our system.  The objective of this work was to 
quantitatively examine the role of the matrix on molecular motor activity and intracellular 
rheology of cells and spheroids within a 3D environment. 
 
Aim 3: Investigating the interaction between the ECM and YAP/TAZ activity in 3D  
 The mechano-sensitive YAP/TAZ signaling pathway, though shown to influence 
ECM mechanics and be correlated with malignant cancers, has not been well 
characterized in a 3D system.  To understand the relationship between the mechanical 
components of the ECM and YAP/TAZ activity, we integrated our 3D spheroid in vitro 
model with tissue clearing to allow for complete visualization of YAP/TAZ activity 
within dense spheroid structures.  The influence of cell-cell and cell-ECM interactions on 
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YAP/TAZ activity can be studied within this integrated physiologically relevant 3D 
model.  With this aim, we connected structure and mechanics studied in the previous 
section with cell signaling by investigating the relationship between the ECM and the 
YAP/TAZ pathway. 
 
1.2 Structure of Thesis  
 The structure of the thesis consists of background information, discussion of the 
proposed aims, and conclusions and future directions.  Each chapter in the aims section 
will discuss an aim, its methods, analysis, and results. 
Chapter 2 provides background information and literature on breast cancer and 
current treatment methods.  In addition, the chapter describes the physical changes the 
tumor microenvironment undergoes with cancer progression and the cell-ECM 
mechanotransduction process.  The chapter also details the YAP/TAZ signaling pathway 
and its connection to mechanotransduction and cancer.  Chapter 2 concludes with an 
overview of in vitro models and measurement techniques in 3D.  
 In the following chapters, we present our results from the proposed aims.  Chapter 
3 describes our work in which we assessed the impact of the ECM, drug incubation time, 
and cell type on drug response in 2D and 3D single cell embedded models.  Chapter 4 
details the characterization of the mechanical properties of cancer cells in 3D matrices in 
response to collagen concentration and cytoskeletal inhibitors.  Chapter 5 reports on the 
development of a 3D in vitro spheroid model integrated with tissue clearing to investigate 
YAP/TAZ activity within a dense structure.   Chapter 6 summarizes the major 
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conclusions of the work and highlights potential future directions.  
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CHAPTER 2. Background 
 
2.1 Overview of Breast Cancer 
Breast cancer is the second leading cause of cancer death in U.S. women with 
about 41,400 deaths expected in 201820.  Incidence rates for breast cancer in women are 
the highest compared to those of other types of cancer and steadily increasing as shown 
in Figure 2-120.  Approximately 246,000 new cases of invasive breast cancer and 61,000 
cases of non-invasive breast cancer will be diagnosed in women in 201821,22.  In addition, 
about 12% of women in the U.S. will develop invasive breast cancer at some point during 
their lives22.  Though death rates have been declining due to improvements in early 
detection and treatment, highly metastatic and resistant forms of breast cancer continue to 
occur in patients23,24.  Because these cancers are less or not responsive to normal 
chemotherapy, survival rates for these patients are lower25.  Therefore, there is a need to 
understand cancer development and progression in order to improve treatment efficacy 
and patient outcome.  
   
2.2 Current State of Breast Cancer Treatment  
Due to the high complexity and individual variability of breast cancer, several 
treatments strategies have been developed.  Current conventional breast cancer treatment 
options include surgery, radiation therapy, and chemotherapy.  In addition to the principal 
treatment strategy chosen for the patient, other therapeutic approaches may be used in 
parallel to ensure cancer cells are eliminated while leaving the normal tissue unharmed26.  
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Breast cancer is generally treated with different combinations of surgery, 
chemotherapy, and radiation therapy depending on the type and stage of the disease27.  
Breast conservation surgery or mastectomy is usually the first treatment performed on 
patients once a tumor is discovered28,29.  Tumor resection, the most direct method for 
removing the cancer, involves removing the tumor and a small area surrounding the 
tumor30.  If the tumor is too large for the surgery to be possible or too risky for the 
patient, chemotherapy can be administered to the patient to decrease the size of the tumor 
before surgery.  Radiation therapy can also be paired with surgery to target cancer cells.  
Ionizing radiation in the form of photons or charged particles targets cancer cells and 
causes irreparable DNA damage31.  Cancer cells express a higher proliferation rate, but 
cannot efficiently repair damage done to their DNA.  As a result, the radiation kills the 
cancer cells or reduces their replicative capacity32.  
After surgery, chemotherapy is started to kill remaining tumor cells not removed 
by surgery and reduce the risk of relapse29,33.  Chemotherapy involves the use of 
cytotoxic compounds that target rapidly dividing cells by damaging DNA or disrupting 
the cell division cycle34.  Classes of chemotherapeutics include alkylating agents, anti-
microtubules, and anti-metabolites35.  These compounds disrupt the cell cycle by 
damaging DNA, blocking DNA replication, preventing the formation of microtubules, or 
stabilizing microtubules.  Though the chemotherapeutic can be effective, the drugs 
broadly affect other rapidly dividing cells such as those of the gastrointestinal tract or hair 
cells.  As a result, patients can have harmful side effects when taking 
chemotherapeutics36.  Figure 2-2 shows the treatment pathway for early breast cancer 
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with treatment selection based on the size and location of the patient’s tumor29.  
Molecular profiling of the patient’s breast cancer with estrogen (ER) and 
progesterone (PR) receptor testing, Human epidermal growth factor type 2 receptor 
(HER2/neu) testing, and multigene testing can help influence the selection of therapy37.  
The receptor tests measure the amount of ER, PR, and HER2 receptors there are in the 
cancer tissue38.  Based on these tests, the breast cancer is classified as hormone receptor 
positive/negative (ER and/or PR + or ER and/or PR -), HER2/neu positive/negative, or 
triple negative (negative for ER, PR, and HER2/neu receptors)39.  Multigene tests such as 
MammaPrint and Oncotype DX can help predict if the patient’s stage I or stage II breast 
cancer will spread to other parts of the body.  If there is a high risk that the cancer will 
spread to other parts of the body, chemotherapy may be administered to lower the 
risk40,41.  Though these molecular tests provide valuable information about breast cancer 
type and possible treatment options, the critical role of the breast tumor 
microenvironment on cancer development and progression is often overlooked.  
Though the breast cancer treatment regime is successful for many patients, some 
patients do not respond to the treatment or develop drug resistance and require a different 
drug or combination of drugs42.  Patients that initially respond to chemotherapy may 
show a loss of response and tumor regrowth.  The chemotherapy treatment cycle has been 
shown to put a selective pressure on cancer cells, which selects for resistant cells that 
repopulate the tumor.  Causes of reduced drug response include inherent resistance or 
acquired resistance following treatment with the drug43,44.  
Cancer cells can acquire resistance to chemotherapy through several different 
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mechanisms including altered transport of the drug across the cell membrane, cell death 
inhibition, drug target alteration, and DNA damage repair45,46.  Several theories of tumor-
cell drug resistance have been developed to explain how the cancer cells use these 
mechanisms to survive drug treatment and continue to proliferate.  
In the most common model of drug resistance, cells in the tumor acquire genetic 
changes that lead to drug resistance.  These cells survive chemotherapy and proliferate to 
form a tumor that is composed of the drug resistant cells47.  An alternative model 
indicates that cancer stem cells in the tumor are resistant to chemotherapy due to their 
quiescence and DNA repair ability.  Cancer stem cells are a highly malignant tumor cell 
with high capacity for self-renewal and differentiation.  The cancer stem cells are able to 
proliferate indeterminately and form into tumor cells48,49.  After chemotherapy, the 
committed tumor cells are killed and the remaining cancer stem cells repopulate the 
tumor.  In the acquired resistance model, cancer stem cells survive the chemotherapy and 
undergo mutations through mechanisms such as point mutations or gene amplification. 
As a result, the stem cells obtain a drug resistance and produce a population of cells 
resistant to the applied chemotherapeutic24,50.  In the intrinsic resistance model, the stem 
cells and the differentiated cells are inherently drug resistant.  Therefore, the therapies 
have little or no effect on the cells, which leads to the growth of the tumor46.  
These models of drug resistance explain why most conventional cancer therapy 
fails in patients.  Through chemotherapy may kill most cells in a tumor, drug resistant or 
cancer stem cells may remain after treatment and require the patient to undergo a 
different treatment regimen.  Currently, the factors that promote and reduce 
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chemoresistance are not well understood45–47.  Though the mechanisms that mediate drug 
response at the cellular level are well characterized, recent research suggests that 
mechanisms that involve the tumor microenvironment are also significant determinants of 
drug response and cellular behavior51.  Therefore, different approaches for identifying 
and combating drug resistance need to be studied in order to develop new therapeutic 
targets and more effective treatment strategies.  
 
2.3 Breast Cancer Tumor Microenvironment 
Cancer is often described as abnormal genomic mutations of normal cells, but 
ECM mechanical cues have also been shown to significantly contribute to cancer 
progression52.  Cancer has been shown to influence and be influenced by intracellular 
mechanical properties53.  For example, various changes occur in the extracellular matrix 
with breast cancer progression such as an increase in collagen density, an increase in 
collagen deposition in the stroma, and a stiffening of the ECM54,55.  Clinical research has 
recently found that stiff and dense breast tissue results in greater breast tumor growth and 
tumor metastasis9,56,57.  Although most cancer research has focused on how biochemical 
signals and molecular mechanisms regulate cellular processes, these clinical studies 
indicate that the mechanical and physical forces of the tumor microenvironment also have 
an important role in regulating cellular functions42.  Therefore, the role of the tumor 
microenvironment in cancer development and progression must be considered when 
designing treatment strategies.   
To understand how the tumor microenvironment affects tumor progression, it is 
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important to understand the structure of the ECM and the normal mammary gland.  The 
ECM is a dynamic and complex environment that interacts with and is remodeled by 
cells58.  The ECM is composed of glycoproteins, proteoglycans, and polysaccharides in 
addition to proteins such as collagen, laminin, and fibronectin.  These proteins distribute 
and activate growth factors and allow for interaction with the cells59.  Though the ECM 
may appear to merely serve as a scaffold for cells, the ECM is involved in directing 
several cellular processes such as assisting in tissue organization, determining cell fate, 
and providing a substrate for motility60.   
The normal mammary gland is composed of a branching ductal network with 
lobules at the terminal ends.  The branching ductal networks contain a hollow lumen 
surrounded by a mammary epithelium, which is organized into an inner luminal 
compartment and an outer basal compartment3.  The inner layer comprises of a single 
layer of polarized luminal epithelial cells that differentiate into milk-producing alveoli.  
The outer layer is composed of basal myoepithelial cells that contract and push milk 
through the ducts61.  The entire epithelial ductal tree structure is enclosed by a laminin-
rich basement membrane and surrounded by the mammary fat pad and stromal 
fibroblasts62. The intralobular stroma is a loose connective tissue that contains 
microvasculature, small lymphatic channels, adipocytes, fibroblasts, and inflammatory 
cells.  The interstitial stroma, which consists of dense connective tissue, surrounds the 
intralobular stroma and ductal network3,63.  
As a tumor progresses, several mechanical changes occur in the mammary tissue.  
Uncontrolled growth of cells disrupts the breast architecture and leads to ECM 
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remodeling and stiffening as shown in Figure 2-33,54,64.  Due to the continuous 
remodeling of the tumor microenvironment, breast cancer tissue has been found to 
become several times stiffer than normal tissue.  The stiffness of the mammary tissue has 
been shown to increase from 200 Pa in healthy mammary tissue to over 4,000 Pa in 
tumor-associated tissue62.  Studies examining the relationship between tissue stiffening 
and tumor progression found that ECM stiffening alters integrin signaling, elevates Rho-
dependent cytoskeletal tension, disrupts adherens junctions, and increases focal adhesion 
formation.  This stiffening of the ECM alters cellular behavior to a malignant state and 
may lead to tumor progression61,63.   
During tumor progression, occurrence of increased ECM deposition is associated 
with a poorer predicted outcome in breast cancer patients.  Accordingly, recent clinical 
studies have found that higher breast density is associated with an increase in stromal 
collagen and an increased risk of developing breast cancer61,64.  Increased density due to 
elevated collagen concentration is a risk factor for the development of breast cancer with 
women with dense breasts having a 2 to 6 times higher tumor formation susceptibility.  In 
addition, an increase in ECM rigidity has been shown to increase the number and activity 
of invadopodia, which may suggest that increases in tissue rigidity result in increased 
cellular invasiveness and tumor progression64.  However, the underlying mechanism for 
the higher breast density risk factor is not known3,65. 
The stiffness and structure of the ECM also influence cell speed and the direction 
of migration.  Cells have been shown preferentially migrate from softer to stiffer 2D 
substrates in the process known as durotaxis66.  Breast tumors are stiffer than the 
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surrounding tissue and contain different stiffness regions that could guide cell 
migration67.  A study in mice observed that tumor cells preferentially invade along 
collagen fibers into the stroma68.  Stiffer matrices are more likely to have an aligned fiber 
structure and have also been shown to promote tumor cell proliferation.  The ECM 
structure changes with tumor progression with cancer cells influencing the organization 
of the microenvironment69.  Tumor-associated collagen signatures (TACS) describe the 
changes in the deposition and orientation of the collagen around the tumor and have been 
shown to be useful as prognostic signatures for patient survival70.   
Increased deposition of collagen near the tumor that occurs in early tumor 
formation is termed TACS- 1.   As the tumor increases in size, the fibers align parallel to 
the tumor and is described as TACS-2.  Remodeling of the stroma in later stages of 
cancer can lead to collagen fiber alignment perpendicular to the tumor, which is 
characterized by TACS-3, enabling cancer cells to migrate along those fibers70,71.  Tumor 
cells have been observed to preferentially invade along the straightened aligned collagen 
fibers, which can lead to cancer cell invasion into the surrounding area72.  Studying the 
collagen structure and stiffness may allow for a more accurate prediction of disease 
recurrence and patient survival and help develop therapies that target the matrix 
alignment.  Consequently, there is a need to understand how the changes in the stiffness 
and structure of the ECM that occur with breast cancer progression influence cellular 
behavior.  
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2.4 Cell-ECM Mechanotransduction  
Cells transduce mechanical forces in their microenvironment into biochemical 
signals through the process of mechanotransduction63. This process is involved in 
regulating several key cellular processes including morphogenesis, cell migration, 
proliferation, differentiation, and apoptosis65.  Cellular behavior is directed by 
mechanical cues from the surrounding ECM and neighboring cells as well as internal 
cell-generated forces.  The focal adhesion complex, which consists of integrins and 
signaling proteins, links the actomyosin skeleton with the ECM to transmit external 
forces to inside the cell73.  Therefore, the ECM structure has a dynamic role in regulating 
cell behavior and tumor progression. 
The cytoskeleton is involved in many essential cell functions including migration, 
adhesion, and mechanotransduction74.  Adhesion complexes link the cytoskeleton of the 
cell to its external environment75.  The structural properties and stiffness exhibited by the 
cell are influenced by the main components of the cytoskeletal network, including actin 
filaments, intermediate filaments, microtubules, molecular motors, and crosslinking 
proteins76.  The heterogeneous cytoplasm and forces spread through the ECM also affect 
the mechanical behavior of cells77,78.  Within the cytoplasm, many active processes occur 
such as molecular motors transporting ATP or macromolecules along microtubule tracks 
and myosin motors contracting actin filaments79,80.  The combined activity of these 
motors and active forces influence important cellular processes and may impact the 
motion and macromolecular transport within the cytoplasm81,82.  
 Integrins, a family of heterodimeric transmembrane proteins, allow cells to adhere 
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to the surrounding ECM.  Integrins also function as the link between extracellular and 
intracellular mechanical signaling73.  Focal adhesions, comprised of integrin clusters and 
other protein assemblies, connect the cytoskeleton of the cell to the ECM and transmit 
mechanical force and regulatory signals83.  Filamentous actin interacts with the focal 
adhesions and works with myosin to form the cell contractile apparatus, which provides 
cells with structural integrity84.  The interaction of these cellular and extracellular 
components is shown in Figure 2-485.   
In addition to cell-ECM interactions, cell-cell interactions allow cells to 
mechanically interact with each other.  Through adherens junctions, cells transduce 
mechanical forces between each other as they link with each other via cadherin7.  Recent 
studies have suggested that the YAP/TAZ signaling pathway is involved in both 
chemoresistance and mechanotransduction19,86.  Therefore, it is a pathway of interest to 
study the potential role mechanotransductive elements in the development and 
progression of aggressive breast cancer.   
 
2.5 YAP/TAZ Signaling Pathway 
The Yorkie-homologues Yes-associated protein (YAP) and transcriptional 
coactivator with PDZ binding motif (TAZ) are sensors that communicate with the 
structural and mechanical components of the cell microenvironment86,87.  These 
transcriptional coactivators move between the cytoplasm and the nucleus where they bind 
to specific transcription factors such as TEAD, which enables the transcription of genes 
encoding proteins involved in several cell processes, such as organ size control and 
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cellular differentiation88.  YAP/TAZ transduce the structural features of the cell, which 
are connected to the chemical and physical features of the cell’s microenvironment.  
Mechanical inputs such as ECM stiffness, cytoskeletal tension, and cell shape directly 
regulate YAP and TAZ activity.  Therefore, the response of YAP/TAZ to cellular events 
reflects changes that occur at the level of whole tissues89.  
YAP/TAZ activation is also involved in inducing cancer stem cell characteristics, 
proliferation, chemoresistance, and metastasis18,19.  Analysis of clinical datasets showed 
elevated expression of YAP/TAZ gene signatures correlates with high histological grade, 
stem cell signatures, metastasis, and poor outcome90.  In addition, TAZ overexpression 
was found to increase metastatic ability and content of tumor initiating cells91,92.  Recent 
studies have identified YAP/TAZ regulation by mechanotransduction as integral for 
chemoresistance development. For example, one study showed that as cells acquired 
resistance, polymerization of actin stress fibers, and YAP/TAZ accumulation in the 
nucleus of resistant cells increased9,93.  
To explain why tumor cells with activated YAP/TAZ have resistance to 
chemotherapeutic drugs, one group hypothesizes that the cell increase in responsiveness 
to ECM rigidity and the stiffening of the microenvironment occur simultaneously to 
induce YAP/TAZ nuclear accumulation in cancer cells as shown in Figure 2-518,.  The 
development of drug resistance was found to occur with YAP/TAZ activation, leading to 
uncontrolled cell survival and proliferation18,94.  Analysis of clinical data has also shown 
that YAP/TAZ related genes are upregulated in aggressive grade 3 tumors91.  To 
determine whether the altered ECM environment associated with high grade tumors 
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activates YAP/TAZ signaling, the mechanical and molecular relationship between the 
cancer cells and ECM must be understood.  
 
2.6 In vitro 3D Drug Studies  
Most in vitro drug research observes the behavior of cells with 2D studies and 
fails to predict cellular behavior in an in vivo system15,95.  The 2D assays involve cells 
cultured on hard plastic or glass substrates96,97.  However, cells in vivo are surrounded by 
a 3D matrix and have different morphology and cellular structure compared to cells in a 
2D environment as shown in Figure 2-616,98.  Unlike in 2D, the 3D matrix impedes the 
movement of the cell and limits diffusion of chemicals and compounds17.  Cells within a 
3D environment are also directly in contact with the matrix along all spatial dimensions99.  
Consequently, the information from 2D studies can lead to misrepresentative results and 
inaccurate translation to in vivo animal models15,100.  
Though the prevalence of studies in 3D is increasing, many studies do not 
incorporate physiologically relevant characteristics or integrate changes that occur in the 
matrix101,102.  The remodeling of the microenvironment with tumor progression must be 
considered to develop an accurate model of breast cancer.  Clinical and mouse studies 
looking at the association between ECM stiffening and tumor progression have found that 
matrix stiffening changes integrin signaling, increases Rho-dependent cytoskeletal 
tension, disrupts adherens junctions, and increases focal adhesion formation. These 
changes alter cellular behavior and lead to tumor progression and malignancy61,63.  
Aggressive breast tumors, which are more difficult to treat due to the rapid growth and 
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metastasis of cells, have higher stiffness and contain increased collagen 
concentration103,104.  Because cellular mechanical behavior changes with varying collagen 
concentration, the ECM may contribute to the altered intracellular activity and drug 
response of cancer cells.   
Natural matrices made from reconstituted ECM components such as collagen, 
fibrin, fibronectin, and elastin contain intrinsic biochemical cues for the cells.  Collagen 
is a versatile matrix that allows for tuning of pore size, stiffness, and ligand density by 
varying collagen concentration, pH, and polymerization temperature105.  
Transglutaminases can also be used to increase crosslinking of collagen fibers without 
increasing ligand density106.  Though these natural matrices can be heterogeneous, they 
provide an in vivo like environment for cells that can be easily utilized in a 3D model107.  
Therefore, a physiologically relevant 3D model that mimics the stages of tumor 
progression may allow us to understand how changes in the tumor microenvironment and 
ECM stiffening affect tumor behavior and malignancy.   
 
2.7 Measurement Techniques and Imaging in 3D  
While technologies that measure the intracellular behavior of cells in 3D, such as 
particle tracking microrheology and dual optical tweezers, have been developed, the 
relationship between intracellular behavior and the 3D matrix has not been quantitatively 
characterized7,14,15.  Many of the techniques that analyze the mechanical properties of 
cells can only be utilized in 2D conditions and may require direct contact with the cells, 
such as with atomic force microscopy and micropipette aspiration108,109.  To study the 
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interaction between the 3D matrix mechanics and intracellular motor-driven activity, a 
technique that measures the mechanical properties and cellular response to drug treatment 
of cells embedded within a physiologically relevant environment must be used.  
 Though imaging single cells within a 3D matrix is possible, imaging larger or 
denser structures, such as spheroids, becomes difficult due to light penetration 
constraints110.  Spheroids are a tightly packed aggregate of several cells that can be used 
to mimic the behavior and multicellular structure of tumors.  Spheroids can be formed 
using a variety of methods including the hanging drop technique and low adhering round 
bottom plates111.  Spheroids not only provide a system to study cell-cell interactions, but 
also can be embedded within a collagen matrix to capture cell-ECM interactions and 
simulate an in vivo environment112.  Unfortunately, with regular imaging techniques, only 
the outer layer of spheroids can be visualized due to light scattering effects of the cellular 
components110.   
To understand the characteristics of larger spheroids embedded within collagen, a 
method for optically clearing organs can be utilized.  Organs are most commonly 
visualized by cutting several sequential thin sections and imaging each slice 
independently.  However, this approach can lead to damage of individual slices and does 
not provide a view of the entire structure in the context of three dimensions113.  Several 
tissue clearing methods have been recently developed to image thick tissues such as 
mouse organs and entire mouse bodies.  These tissue clearing techniques generally 
equilibrate the refractive index through the sample to reduce light scattering113,114.  The 
CUBIC (clear, unobstructed brain imaging cocktail) procedure comprises of an 
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aminoalcohol mixture that breaks down the dense lipids in organs that block and scatter 
light.  The procedure allows for easy visualization of fluorescently labeled proteins and 
cells within any organ as shown in Figure 2-7115.  CUBIC tissue clearing can be used on a 
spheroid embedded within a matrix to study how the morphological properties of the cell 
are affected in the tumor microenvironment.  Therefore, a 3D model combining a 
physiologically relevant ECM with cells and the ability for mechanical, molecular, and 
morphological analysis may allow for a better understanding of how the tumor 
microenvironment affects cancer progression.  
!
!
! !
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Figure 2-1: Incidence Rates for Different Types of Cancer for Females 
The incidence rates for different types of cancer for females from 1975 to 2014. The rates 
have been age adjusted to the US population in 2000.  Figure taken from Siegel, R. et al. 
(2018)20. 
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Figure 2-2: Treatment Pathway for Early Breast Cancer 
The treatment pathway for early breast cancer depending on the size of the tumor. 
Combinations of surgery, radiation therapy, and chemotherapy are treatment strategies 
used to treat breast cancer. Figure taken from Senkus, E. et al (2015)29 
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Figure 2-3: Changes In Breast Microenvironment With Cancer Progression 
Several changes occur in the breast cancer microenvironment including stiffening of the 
ECM, disruption of the basement membrane, and increase in matricellular proteins. 
Figure taken from Insua-Rodriguez, J. et al. (2016)54. 
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Figure 2-4: Interaction of Extracellular and Intracellular Components 
The extracellular matrix (collagen) is connected with the actin cytoskeleton inside the cell 
via integrins.  Figure taken from Nature Education. (2010)85. 
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Figure 2-5: Influence of Microenvironment on YAP/TAZ and Drug Response 
Cell increase in responsiveness to ECM rigidity and the stiffening of the 
microenvironment occur simultaneously to induce YAP/TAZ nuclear accumulation in 
cancer cells.  Figure taken from Francesca, Z. et al., (2016)18.   
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Figure 2-6: Comparison of 2D and 3D Cell Culture 
In 2D cultures, cells flatten and lose differentiation markers. In 3D cultures, cells regain 
their characteristics as shown by the different behaviors of the epithelial and 
mesenchymal cells. Figure taken from Cukierman, E.  et al., (2007)98. 
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Figure 2-7: CUBIC Cleared Mouse Organs  
Mouse organs with CUBIC clearing treatment become optically clear, allowing for 
visualization of the entire structure.  Figure taken from Susaki, E. et al., (2015)115.  
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CHAPTER 3. Matrix and Drug Incubation Time Influence on Drug Response 
 
 
3.1 Introduction 
In order to characterize how external factors contribute to changes in drug 
response, a reliable method for quantifying and studying drug response in vitro is needed.  
Conventional 2D culture of breast cancer cells on tissue culture-treated polystyrene does 
not accurately represent in vivo conditions.  Cells in a 3D ECM have different shape and 
cytoskeletal structure compared to cells in a flat 2D culture15.  However, these in vitro 
drug research studies assume that the behavior of cells in 2D can be translated to in vivo 
systems.  In addition, previous drug research in 3D has not incorporated varying external 
and extracellular factors such as drug incubation time and matrix stiffness44.  
Administering the drug for only a single time interval may not be relevant based on the 
type of cell type or in vitro model.  In addition, the matrix surrounding the cells limits 
cell movement and diffusion of chemicals and compounds, leading to varying drug 
responses in 2D and 3D116.  Therefore, developing a quantitative and physiologically 
relevant method for studying drug response in a 3D model can provide a better 
understanding of factors that cause a varied drug response in cancerous cells.  To this 
end, we investigated the response of cancerous and non-cancerous cells to varying drug 
incubation times and matrix stiffnesses (Figure 3-1).  
 In the first part of our investigation, the drug response of cancerous and non-
cancerous cells was quantified within a 2D in vitro model.  The 2D monolayer model 
represents conventional cell culture methods that constrain cells to a flat shape and cause 
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an increase in the cell proliferation and alteration of adhesion structures117.  The 2D 
model provided a reference point for comparing the cellular response in a 3D model.  
 To quantify the cellular response to drug treatment in 2D, we determined the half 
maximal inhibitory concentration (IC50) value.  The IC50 value indicates the drug 
concentration required to reduce or inhibit the measured biological or biochemical 
response by half.  Large IC50 values indicate inhibitors that are less effective than 
inhibitors with lower IC50 values.  For example, an increase in the IC50 value indicates a 
higher drug concentration is needed for 50% cell inhibition118.  Pharmacological research 
commonly uses the IC50 as a measure of drug potency for competition binding assays 
and functional antagonist assays.  The IC50 is used in the early steps of the drug 
discovery process to evaluate the functionality of the drug.  This allows pharmaceutical 
companies to screen millions of compounds to determine the ones with the greatest 
efficacy without a high cost or time investment119.  
The human breast cell lines used for comparison were MDA-MB-231 and 
MCF10A cells.  The MDA-MB-231 cells are a triple negative metastatic breast cancer 
derived from the metastasis of a pleural effusion.  The MCF10A cells are a non-
tumorigenic cell line derived from benign proliferative breast tissue120.  
The drug response of cancerous and non-cancerous cells was then quantified 
within a 3D in vitro model.  Cell proliferation is one of the main targets in cancer therapy 
with several drugs targeting the rapidly dividing nature of cancer cells121.  The 
surrounding 3D ECM in a physiological system influences the cell proliferation rate.  
However, in vitro drug screening in 2D fails to accurately represent the interactions and 
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mechanical properties of a natural ECM121,122.  To characterize the difference in cell 
proliferation in 2D and 3D, the cell doubling rate can be determined.  The cell doubling 
rate indicates the amount of time for the cell population to reach double the initial 
number.  Because the cells are embedded within a 3D matrix, measuring cell proliferation 
in 3D is more challenging compared with 2D culture.  However, incorporating a 3D ECM 
provides a more physiologically relevant environment and has shown promising results 
for improving early stage drug screening of cancer drugs123.   
 After determining how the 2D IC50 changes with drug incubation time, we 
compared the drug responses of cancerous and non-cancerous cells in 2D and 3D.  The 
previously described IC50 assay was used to measure the drug response of cells 
embedded within a 3D matrix.  The 3D model improves upon the 2D monolayer by 
capturing the cell-ECM interactions present in vivo and providing a more physiologically 
relevant environment (Figure 3-2).  Consequently, we sought to determine the impact of 
the 3D matrix on cellular response to varying drug incubation times of Paclitaxel.  
In addition to studying how drug incubation time affects the IC50, we studied the 
drug responses of cancerous and non-cancerous cells in varying collagen concentrations.  
The breast microenvironment undergoes several changes with cancer progression 
including stiffening of the ECM and increased collagen deposition56.  Due to these 
changes, current 3D models may not be able to capture the dynamic nature of the tumor 
microenvironment.  For example, a stiffer and denser matrix may increase the cell-ECM 
interactions and change the mechanical behavior of the cell, resulting in a different drug 
response.  A denser matrix may also limit drug diffusion speed and require longer 
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incubation times to reach the desired effect.  Therefore, to recreate the changes the tumor 
ECM undergoes, the 3D model needs to incorporate varying matrix stiffnesses and 
collagen contents.   
By using collagen gels of different concentrations, we can integrate the dynamic 
changes of tumor progression in an in vitro model and study the variations in drug 
response.  To this end, cancerous and non-cancerous cells were embedded within 
collagen gels of varying concentrations and treated with Paclitaxel in order to determine 
how the drug response changes with stiffness and increased collagen.    
 
3.2 Materials and Methods 
3.2.1 Cell Culture in 2D   
The breast cancer cell line MDA-MB-231 and non-cancerous cell line MCF10A 
were purchased from American Type Culture Collection (ATCC).  The MDA-MB-231 
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Fisher Scientific) 
supplemented with 10% fetal bovine serum (FBS, ATCC) and 1% 
penicillin/streptomycin (ATCC) in accordance with manufacture recommendations.  The 
MCF10A cells were cultured in MEGM (Mammary epithelial growth medium, Lonza) 
made with the BulletKit from Lonza.  MEBM was supplemented with 2mL bovine 
pituitary extract, 0.5mL hydrocortisone, 5ml, penicillin-streptomycin, 0.5mL insulin, 
0.5mL epidermal growth factor and 10ng/mL cholera toxin to make MEGM media.  Cell 
lines were maintained in tissue culture treated polystyrene flasks and kept in an incubator 
at 37oC, 5% CO2, and 75% humidity.   
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3.2.2 2D IC50 Determination   
The half maximal inhibitory concentration (IC50) represents the concentration of 
a drug that is required for 50% inhibition in vitro.   A sigmoidal function is fit to the 
experimental data to create a dose-response curve.  The IC50 is calculated based on the 
linear trend of the maximum, minimum, and halfway cell viability values and the 
corresponding drug concentrations (Figure 3-3).  For 2D experiments, cells were plated 
onto a polystyrene 96 well plate at a density of 104 cells/well and allowed to adhere for 24 
hours.  Each experimental condition had 3 replicates on the same well plate.  Drug was 
added to the cells at the following concentrations: 0.5, 5, 10, 50, 100, 500, 100, and 
10,000nM.  After incubation with the drug for the desired amount of time, the media and 
drug solution were removed and a live/dead stain (calcein AM/Ethidium homodimer, 
Sigma Aldrich) was added.  The well plate was incubated for 30 minutes with the 
live/dead stain and the fluorescence signal from the cells was measured by a plate reader.  
3.2.3 2D Cell Doubling Time Determination  
For 2D cell doubling, 150,000 cells were seeded onto a 24 polystyrene tissue 
culture treated well plate.  Cells from 3 wells were trypsinized for 5 minutes and counted 
on a hemocytometer.  The average of the cell counts from the 3 wells was calculated.  
Measurements were taken at 3 time points: 18h, 24h, and 36h. The doubling point was 
determined by finding the time point where the cell count was 300,000.  
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3.2.4 3D Cell Doubling Time Determination  
For 3D cell doubling, 100,000 cells were seeded in a 3mg/mL gel on a 96 well 
plate at a seeding density of 1 x 105 cells/mL.  This allowed for approximately the same 
cell density as in 2D.  High Concentration Rat Tail Type I Collagen (BD Biosciences) 
was combined 1:1 with a buffer solution of 100mM HEPES in 2X PBS.  The solution 
was then diluted with PBS to the desired working concentration.  The collagen solution 
was left to polymerize into a gel for 1 hour in the incubator.  Collagenase Type I 
(Invitrogen) was used at a concentration of 1.5mg/mL in 1x PBS to dissociate the 
collagen matrix surrounding the cells for 1 hour and cells were counted on a 
hemocytometer.  The average of the cell count from 3 wells was calculated at time points 
of 24h, 48h, and 96h.  The doubling point was determined by finding the time point 
where the cell count was 200,000.  
 
3.2.5 2.5D Cell Doubling 
Cells were seeded in a tissue culture treated 96 well plate at 150,000  cells/well 
and allowed to adhere.  After 2 hours, the growth medium was removed and a layer of 3 
mg/mL collagen was pipetted over the cells.  To ensure the monolayer of cells was fully 
covered by the collagen, 70 !L of collagen was used.  After 1 hour, media was added to 
the well to halt the collagen gel polymerization.  To measure cell doubling, the collagen 
was removed using collagenase and trypsin was added to the well to remove the cells.  
Cells from 3 wells were counted using a hemocytometer at 18, 22, 48, and 72 hours.  The 
average of the cell counts from the 3 wells was calculated.  The doubling point was 
determined by finding the time point where the cell count was double the initial number.  
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3.2.6 3D IC50 Determination   
For 3D IC50 determination, a thin layer of collagen was pipetted onto a 96 well 
plate and incubated for 30 minutes.  This collagen layer ensured that the cells sensed the 
stiffness of collagen and not the stiffness of the well plate.  The collagen mixture was 
prepared at the desired concentration of 3 mg/mL containing cells and pipetted onto a 96 
well plate on top of the thin layer of collagen. After allowing the collagen to polymerize 
for 1 hour, media was added to the wells.  The drug concentrations and live/dead methods 
were the same as in the 2D experiments. The incubation time of the live/dead stain was 
45 minutes in the 3D condition to allow for the solution to diffuse through the gel.  
 
3.2.7 Varying Collagen Gel Formulation.   
For 3D IC50 determination with varying collagen concentrations, a thin layer of 
collagen was pipetted onto a 96 well plate and incubated for 30 minutes.  The collagen 
mixture was prepared at the desired concentrations (2, 3, and 4 mg/mL) with cells and 
pipetted onto a 96 well plate on top of the thin layer of collagen of corresponding 
concentration.  The collagen concentration was calculated based on the desired collagen 
concentration and the concentration of the stock collagen. Once the amount of stock 
collagen concentration needed was calculated, the appropriate amount of buffer solution 
and PBS was added to the collagen mixture.  After allowing the collagen to polymerize 
for 1 hour, media was added to the wells.  The drug was incubated for 40 hours and the 
live/dead methods were the same as in the 2D experiments.  The incubation time of the 
live/dead stain was 45 minutes in 3D to allow for the solution to diffuse through the gel.  
! 36 
The shear moduli of the collagen gels were measured using a rheometer with a 40 
mm aluminum cone (2 degrees) geometry (Figure 3-4).  A collagen sample volume of 
590 uL was gelled on the rheometer for 1 hour at 37 oC.  The angular frequency was 1 Hz 
and measurements were taken every 1 minute for a duration of 1 hour.  The G’ and G” 
values were taken as an average of 10 data points in the plateau region, between 50 
minute and 60 minutes (Table 3-1).  Three collagen gel samples were measured for each 
concentration.   
 
3.3 Results 
3.3.1 Quantifying Drug Response in a 2D In vitro Model 
 The IC50 values for cells in the 2D model were determined using the method as 
previously described.  The chemotherapeutic Paclitaxel was incubated at varying 
concentrations for 24, 40, and 70 hours and the IC50 value was calculated based on the % 
cell viability.  The IC50 assay results showed that the cancerous MDA-MB-231 cells had 
higher IC50 values than the non-cancerous MCF10A cells for each corresponding drug 
incubation time point (Figure 3-4).  The higher IC50 values for the cancerous cells 
indicated that more drug was required to reduce cell viability to 50% compared to the 
non-cancerous cells.  
 The IC50 value was also found to decrease with increasing drug incubation time 
for both cell types.  A higher drug concentration was required to inhibit 50% of the cell 
viability at 24 hours of drug incubation time compared to 70 hours.  Since Paclitaxel is a 
cytoskeletal drug that stabilizes microtubules and halts cell division124, a longer drug 
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incubation time may allow for the drug to perturb the cell cycle more effectively, thus 
requiring less drug reach 50% inhibition of cell viability  
 The IC50 assay in a 2D system allows for rapid diagnostic capability and provides 
a general estimate of the drug’s effectiveness119.  However, cells in 2D in vitro models 
have drastically different phenotypes and behaviors compared to cells in a 3D 
environment.  Cells in 2D are adhered to the stiff substrate resulting in a flattened 
morphology, and in direct contact with the surrounding media and drug solution.  
Therefore, we need to determine how the IC50 values of cells in 2D compare to cells in a 
physiologically relevant 3D model.  
 
3.3.2 Determining Drug Response in 3D In vitro Model 
 The cell doubling values for MDA-MB-231 cells in 2D and 3D were found using 
the method previously described.  The cell doubling value in 2D was found to be 
approximately 24 hours while the 3D doubling time was 70 hours (Figure 3-5).  The 
doubling time in 3D may be slower because the cell is not receiving nutrients from the 
media as quickly due to the surrounding matrix.  Instead of being in direct contact with 
the cells, the media must diffuse through the collagen to reach the cells.  In addition, the 
spreading of cells in 2D is not restricted by a matrix, allowing the cells to be stiffer and 
replicate more rapidly.  In contrast, the cells in 3D must degrade or push against the 
matrix in order to divide.  
 To determine how the cell doubling time shifts between 2D and 3D, we used an 
intermediary 2.5D system.  In this 2.5D system, cells are in contact with the 2D substrate 
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and also surrounded by a 3D matrix (Figure 3-6).  The 2.5D doubling time was 34 hours, 
which was in between the values for 2D and 3D proliferation.  The increase in doubling 
time from 2D to 3D indicated that the 3D matrix decreased the proliferation rate of the 
cells.  To compare the IC50 values of 2D and 3D, we used the drug incubation times 
from the previous experiments and performed the IC50 assay.   
Similarly, to the 2D conditions, the MDA-MB-231 cells had higher IC50 values 
than the MCF10A cells for each corresponding drug incubation time point.  In addition, 
the IC50 value decreased with increasing drug incubation time for both cell types.   
Figure 3-6 shows the IC50 curves for the MCF10As and MDA-MB-231 cells in 3mg/mL 
collagen gels with varying drug incubation times.  
 However, the 3D IC50 values were higher than the corresponding 2D IC50 
values.  The higher IC50 value in 3D indicated that more drug was required to inhibit 
50% of the cells.  With the 2D and 3D IC50 assays, we were able to quantify how the 
drug response changes with dimensionality, varying drug incubation times, and different 
cell types.  To understand how the 3D matrix affects the drug response, IC50 assays were 
performed on collagen gels of varying concentrations.   
 
3.3.3 Drug Response in Varying Collagen Concentrations  
Since studies that utilize 3D in vitro systems infrequently incorporate the varying 
density of the ECM with disease progression, the impact of collagen concentration on 
drug response is not well characterized.  By comparing the changes in drug response to 
the 2D condition, the changes in drug response due to matrix variations can be studied.  
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We used the IC50 assay system described in the previous sections and measured the drug 
response for cancerous and non-cancerous cells embedded in 3D matrices of different 
collagen concentrations.  
The 3D IC50 values were determined in 2 mg/mL, 3 mg/mL, and 4 mg/mL 
collagen matrices with 40 hours of drug incubation time with Paclitaxel.  The MDA-MB-
231 cells had higher IC50 values than the MCF10A cells in all collagen concentration 
conditions.  In addition, the IC50 value increased with increasing collagen concentration 
for both cell types.  Figure 3-7 shows the IC50 curves for the MCF10As and MDA-MB-
231 cells in varying collagen concentrations.   
The higher IC50 value in the 4 mg/mL collagen condition indicated that more 
drug was required to kill 50% of cells compared to the 2 mg/mL condition.  From these 
results, we found that varying the matrix also influences the drug response in addition to 
the dimensionality of the culture system and the cell type.  
 
 
3.4 Discussion 
In this chapter, we determined how drug incubation time, dimensionality, cell 
type, and collagen concentration affect the drug response and proliferation rate of cells.  
By quantifying the drug response with an IC50 assay, the changes in drug efficacy due to 
these external factors could be assessed.  Due to the differences in phenotype and lack of 
cell-matrix interactions, 2D cultures do not fully capture fundamental in vivo 
conditions125.  Cells in a 3D environment are surrounded by a physical barrier, which 
results in different behaviors not seen in 2D cultures.  The added dimensionality the cells 
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are experiencing in 3D influences integrin binding sites, intracellular signaling, cell 
migration, and cytoskeletal organization126,127.  For example, fibroblasts on 2D substrates 
exhibit a flattened morphology and were observed to freely migrate and proliferate.  In a 
3D matrix, fibroblasts display a spindle shape normally seen in vivo and require different 
interactions with the microenvironment to migrate and proliferate128,129.  
The 3D model of single cells embedded within collagen matrices provides a more 
physiologically relevant environment by eliminating the unnatural cell polarization 
associated with 2D culture.  With this 3D model, the influence of cell-ECM interactions 
on drug response could be studied.  Consequently, the 3D model yielded different drug 
responses than the 2D monolayer.  The IC50 values for the time dependence and collagen 
matrix experiments are shown in Table 3-1.  
From our IC50 assays in which drug incubation time was varied, cells in 3D were 
found to have a higher IC50 values than cells in 2D.  This higher IC50 in 3D could be 
due to the drug not being able to rapidly diffuse into the collagen matrix.  In a 2D culture, 
cells are in direct contact with the drug and media mixture.  In contrast, cells in 3D are 
surrounded by a collagen matrix that physically hinders the diffusion of the media and 
drug solution.  Collagen matrices at physiological concentrations have been found to 
impede molecular diffusion.  The collagen gels were found to be representative of in vivo 
diffusion measurements in tumors of comparable collagen concentration, suggesting that 
in vitro gel models can be used as a representative model to study diffusion in 
tissues130,131.   
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Cells in 3D have also been shown to have a slower replication time than cells in 
2D132.  The higher stiffness matrix acts as a barrier and impedes the proliferation of cells.  
Unlike in 2D where a cell adhered on a higher stiffness substrate increases cell 
proliferation, cells in stiffer 3D matrices were found to have lower proliferation rates.  
Cells must remodel their extracellular surroundings in order to migrate and proliferate 
using enzymes such as matrix metalloproteinases.  However, there is no physical 
obstruction for cells in 2D as long as there is space on the substrate for the cells to 
expand132–134.  Since Paclitaxel is a drug that affects the microtubules, cells that divide 
quickly are more likely to be affected124.  As a result, cells in 3D and the stiffer collagen 
matrices may result in a higher IC50 because they are not replicating as quickly as cells 
in 2D or in softer matrices and therefore avoiding the effects of the drug.  
In summary, our 3D in vitro system provides more physiologically relevant 
conditions and offers insight on how to improve drug research studies.  By understanding 
the effects of stiffening tissue and chemotherapeutic dosage length, treatment strategies 
can be developed to maximize the cellular drug response and decrease cancerous cell 
proliferation rate.  With this characterization of how the external factors influence drug 
response, we next investigated how the microenvironment affects the intracellular 
mechanical properties in 3D. 
  
! 42 
 
Figure 3-1: ECM Stiffening and Drug Incubation Time Effect on Drug Response 
Schematic showing an overview of factors studied in this section (circled in blue).  A cell 
is shown embedded within a 3D matrix with varying ECM stiffness and drug incubation 
times.  
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Figure 3-2: Cells in 2D and 3D In Vito Models 
The in vitro models investigated in this study were a) 2D monolayer and b) 3D diffusely 
embedded cells.  For the 3D model, cells were embedded within 3 mg/mL collagen type-I 
gels.  The same media was used in both models.   
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Figure 3-3: Determination of IC50  
The IC50 represents the concentration of a drug that is required for 50% inhibition in 
vitro.  The IC50 is calculated based on the linear trend of the maximum, minimum, and 
halfway cell viability values and the corresponding drug concentrations. 
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Figure 3-4: Shear Modulus of Collagen Gels 
The shear modulus of collagen gels was measured using a rheometer with a 40mm 
aluminum cone (2 degrees) geometry.  The angular frequency was 1 Hz and 
measurements were taken every minute for a duration of 1 hour.  The G’ and G” values 
were taken as an average of 10 data points between 50 minute and 60 minutes.      
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Table 3-1: Shear Modulus Values of Collagen Gels 
The average and standard deviation of shear modulus values for 1-4 mg/mL collagen 
gels. 
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Figure 3-5: Drug Incubation Time in 2D of MCF10A and MDA-MB-231 Cells 
The 2D IC50 values of a) MCF10A cells and b) MDA-MB-231 cells following treatment 
with varying Paclitaxel concentrations incubated for 24, 40, and 70 hours. Three wells 
were measured for each experimental condition and the results are shown as mean + S.D.  
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Figure 3-6: 2D and 3D Cell Doubling of MDA-MB-231 Cells 
The cell doubling values of MDA-MB-231 cells a) in 2D and b) embedded in 3 mg/mL 
collagen.  Cells were counted at certain time points and the data was fit to an exponential 
curve.  
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Figure 3-7: Cell Proliferation in a 2.5D System  
Cell proliferation changes depending on the surrounding environment. a) Schematic of 
2D culture with 3D matrix embedded culture (2.5D) b) Cell doubling time of 2D culture 
and 3D matrix embedded culture were 23 and 34 hours, respectively. 
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Figure 3-8: Drug Incubation Time in 3D of MCF10A and MDA-MB-231 Cells 
The 3D IC50 values of a) MCF10A cells and b) MDA-MB-231 cells embedded in 3 
mg/mL collagen following treatment with varying Paclitaxel concentrations incubated for 
24, 40, and 70 hours. Three wells were measured for each experimental condition and the 
results are shown as mean + S.D. 
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Figure 3-9: Matrix Density effect on IC50 of MCF10A and MDA-MB-231 Cells 
The 3D IC50 values of a) MCF10A cells and b) MDA-MB-231 cells embedded in 2, 3, 
and 4 mg/mL collagen following treatment with varying Paclitaxel concentrations 
incubated for 40 hours.  Three wells were measured for each experimental condition and 
the results are shown as mean + S.D. 
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Table 3-2: Time Dependence and Matrix Density IC50 Values 
The IC50 values for the MDA-MB-231 cells and MCF10A cells a) with varying drug 
incubation times (24, 40, and 70 hours) in 2D and 3D conditions and b) in varying 
collagen densities (2 mg/mL, 3 mg/mL, and 4 mg/mL) with 40 hours of drug incubation. 
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CHAPTER 4. Microenvironment Impact on Mechanical Behavior of Cells  
 
4.1 Introduction 
Though the ECM may appear to simply function as a scaffold for cellular 
organization, it is involved in a variety of cellular processes including growth, migration, 
and signaling59,135. For example, the ECM anchors cells through adhesions, mediates 
extracellular signaling cues via integrins, allows a matrix for migration of cells, and 
provides barriers between tissues4,136.  Due to the interdependence between the ECM and 
cells, dysregulation of this amalgamation due to a disease state can negatively impact the 
highly linked system3,58,137. 
Several disease states such as cancer and inflammation have been shown to 
impact and are impacted by intracellular mechanical properties53.  For example, breast 
cancer leads to several changes in the ECM composition and organization including an 
increase in stromal collagen, disruption of the basement membrane, and stiffening of the 
ECM54,55,138.  In recent clinical studies, stiff and dense breast tissue has been found to 
drive breast tumor growth and increase tumor metastasis.  Since the breast 
microenvironment is continuously remodeled with cancer progression, the elastic 
modulus of the tumor stroma has been found to be up to 5 times times stiffer than the 
normal mammary gland7,139,140.   
These changes in the ECM are widely observed among cancerous tissue and are 
believed to be an influence in cancer development and progression141,142.  ECM 
remodeling can lead to alterations in cell signaling and increased invasiveness due to 
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increased deposition of fibers and loss of normal tissue architecture3,143.  Disruption of 
the basement membrane may also facilitate the extravasation of cancer cells via increased 
deposition and alignment of collagen fibers72,144.  Because the ECM characteristics are 
interdependent with cellular functions, dysregulation within the surrounding matrix due 
to tumor formation may affect normal cellular signaling and behavior9.  To understand 
how changes in collagen concentration and ECM stiffening affect cell malignancy, the 
stages of tumor progression need to be further studied.  
 The interaction between the ECM and the intracellular mechanics of cells remains 
unclear though there are new technologies to measure the mechanical properties of cells 
in 3D145,146.  For example, techniques such as atomic force microscopy and micropipette 
aspiration can measure the overall stiffness of the cell, but require direct contact with the 
cell and can only be used in 2D conditions108,109.  Though particle tracking microrheology 
and dual optical tweezers allow for the mechanical properties of cells to be measured in 
3D, the cell-ECM interaction has not been well characterized147.  A 3D model is 
necessary because it provides a more physiologically relevant environment to study cell-
matrix interactions since the cells are in contact with the matrix in all spatial 
dimensions99,146.  
 In addition to being responsible for the structural properties and stiffness 
exhibited by the cell53, the cytoplasm of the cell contains many active processes such as 
transport of macromolecules by molecular motors and contraction of actin filaments by 
myosin motors79,80.  The activity of these motors and active forces within the cell 
influence the motion and transport within the cytoplasm82.  To directly quantify the 
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dynamic intracellular state of the cytoplasm and the impact of the ECM on intracellular 
activity, we utilize particle-tracking microrheology.  Microrheology is a technique that 
quantifies the intracellular mechanics and motor-driven activity by measuring the 
displacement of cytoplasmic fluctuations148,149.  This method is ideal because 
measurements can be made within a 3D matrix without physically disrupting the cell or 
the environment.  The matrix can be modulated without affecting the data collection and 
various drugs can be added to the model to study the cellular response to drug treatment.  
Several methods are available to measure the mechanical properties of cells such 
as atomic force microscopy, micropillar arrays, and magnetic twisting cytometry.  
However, these methods involve a 2D environment, require direct contact with the cell, 
and are mostly measuring the surface mechanics of the cells150.  Microrheology is a 
technique used to measure the rheological properties of a medium via the trajectory of 
particles.  In the case of mitochondria tracking microrheology, the tracked particles are 
the mitochondria and the medium is the cell.  Microrheology allows for the measurement 
of the physical characteristics and behavior of cells within a 3D environment and does 
not require perturbation of the environment or cell151.  As a result, the values from 
microrheology may not corroborate with the measurements of the cells in 2D due to the 
difference in dimensionality and measurement of the internal cell mechanics instead of 
the surface mechanics.  Measurements can also vary by several fold within the 2D 
measurement methods due to variations in the level of applied stress, the geometry of the 
probe, and the location measured in the cell150.   
 In this chapter, we investigated the interaction between the ECM and cytoskeletal 
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drugs on intracellular rheology within a 3D matrix (Figure 4-1).  The real time data 
collected from within a cell will allow us to study how external changes affect the 
internal mechanical behavior.  We quantified the intracellular mechanical activity of 
cancerous and non-cancerous cells in a 3D single cell embedded model to determine how 
the cells respond to a changing matrix and drug treatment.  We also utilized a 3D 
spheroid model to study how cell-cell and cell-matrix interactions are affected within a 
3D ECM.  Through this approach, we can analyze how different collagen concentrations 
affect cellular stiffness and molecular motor activity.  Furthermore, we can study how the 
mechanical properties of the matrix regulate passive and active intracellular fluctuations 
when treated with different cytoskeletal drugs.   
  
4.2 Materials and Methods 
4.2.1 Cell Culture   
The metastatic breast adenocarcinoma cell line MDA-MB-231 (ATCC) was 
maintained in tissue culture treated flasks and kept in an incubator at 37˚C, 5% CO2, and 
75% humidity.  The MDA-MB-231 cells were cultured in DMEM (Dulbecco's Modified 
Eagle Medium, Life Technologies) supplemented with 10% fetal bovine serum (ATCC) 
and 1% (v/v) penicillin-streptomycin (ATCC), in accordance with manufacturer 
recommendations.  MCF10A was cultured in Growth Media according to a previously 
published protocol120. 
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4.2.2 Collagen Gel Characterization   
The shear moduli of our collagen gels were measured using a rheometer with a 
40mm aluminum cone (2 degrees) geometry.  A collagen sample volume of 590uL was 
gelled on the rheometer for 1 hour at 37˚C.  The angular frequency was 1Hz and 
measurements were taken every 1 minute for a duration of 1 hour.  The G’ and G” values 
were taken as an average of 10 data points in the plateau region, between 50 minute and 
60 minutes.  Three collagen gel samples were measured for each concentration. 
4.2.3 Single Cell Microrheology   
Microrheology is a technique used to measure the rheological properties of a 
medium via measurement of the trajectory of particles.  Mitochondria were used as the 
tracer particles because they have comparable MSD to microinjected particles, while 
being endogenous and profuse throughout the cell152,153.  The procedure is as described 
previously151,154.  Briefly, MDA-MB-231 breast cancer cells are seeded in 3D collagen I 
gels of different concentrations for 24 hours. Type I collagen from rat tail (BD 
Biosciences) was added to an equal volume of 1x neutralizing solution (100 mM HEPES 
buffer in 2x phosphate buffered saline, pH 7.3).  The wells were flipped every 2 minutes 
for a total of 10 minutes to ensure the cells did not sink to the bottom of the well.  After 
24 hours, fluorescent MitoTracker dye (Life Technologies) was incubated with the cells 
for 1 hour at 37˚C, 5% CO2.  Cells greater than 100 µm above the bottom of the glass 
were tracked for 100 seconds at 50 ms per frame using a confocal microscope. At least 9 
individual cells were tracked for each condition with at least 50 total mitochondria 
tracked (Figure 4-2).  Cells that appeared to be dividing were avoided in the 
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microrheology and imaging experiments in order to focus on single cells. 
The microrheology measurements were concurrently verified with optical 
tweezers152. A sinusoidal oscillation as a function of frequency on a 500 nm diameter 
probe particle within the cells was used.  The trap stiffness was determined and the 
resultant displacement of the bead was measured at a specified sinusoidal trap oscillation 
and frequency to measure the full frequency dependent modulus of the cytoplasm.  The 
optical tweezer measurements determined that the cytoplasm is an elastic solid, which 
confirmed the results from the microrheology measurements.   
The movement of the mitochondria was also compared to injected particle 
microrheology152.  The movement of the mitochondria was found to have a similar force 
spectrum and same frequency dependence as the probe particles. Mitochondria and other 
endogenous granules have been used in particle tracking microrheology experiments and 
have been found to have trends comparable to those of injected beads152,153.   
4.2.4 Confocal Imaging.   
Images were acquired on a spinning disk confocal microscope (Leica) with an 
electron multiplying CCD camera (Hamamatsu Photonics).  A 63x 1.4NA oil immersion 
objective and dual lasers for exciting GFP and mCherry were used.  Samples were 
contained in an incubation chamber on the microscope stage at 37˚C, 5% CO2, and 75% 
humidity throughout the imaging.  Micro-Manager Software was used for the image 
acquisition.  Because the image capture is 100 seconds per cell, no large focal drifts were 
observed.  The change of collagen concentration alone did not appear to affect the image 
quality.  Representative images of the cell and mitochondria in 1-4mg/mL collagen gels 
! 59 
can be found in Figure 4-3.   
4.2.5 Single Cell Data Analysis.   
Imaris software (Bitplane) was used to trace the displacement vs. time curve for 
each tracer (Figure 4-2).  The data were then analyzed in MatLab as previously 
described151. Tracers that could be tracked for longer than 50 seconds were kept for 
statistical analysis.  The mean-squared displacements (MSDs) were calculated and net 
displacements were subtracted for each tracer to account for drift and persistent motions.  
The exponent β was calculated from the logarithmic slope of the MSD.  The standard 
error of the mean (s.e.m.) was used to determine the error bars.  Statistical significance 
was calculated from one-way ANOVA tests for p<0.05, unless otherwise noted.  
4.2.6 Drug Treatments.   
GM6001 (Sigma-Aldrich) is a broad spectrum MMP inhibitor.  Cells were treated 
with 20 µM GM6001, mixed in dimethylsulfoxide (DMSO) and added to DMEM, for at 
least 24 hours prior to the microrheology experiments.  Paclitaxel (Sigma-Aldrich) 
stabilizes microtubules in cells causing mitotic arrest.  Cells were treated with 1000 nM 
Paclitaxel, dissolved in DMSO and added to DMEM, for at least 24 hours prior to the 
microrheology experiments. Y27632 is a ROCK inhibitor that binds to the catalytic site 
of ROCK kinases. Cells were treated with 20 µM of Y27632, dissolved in DMSO, and 
added to DMEM for at least 1 hour prior to the microrheology experiments.  Vehicle 
control experiments with DMSO alone were performed to rule out any effects from 
DMSO.  We performed the vehicle control experiment using 0.1% DMSO (maximum 
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amount used in any drug treated case) incubated for 24 hours in 1-4 mg/mL collagen 
gels.  Cells treated with DMSO were found to have similar MSD and β curves compared 
with the corresponding untreated collagen concentration (Figure 4-6).  
4.2.7 Spheroid Formulation   
Cells were trypsinized from a cell culture flask and counted on a hemocytometer.  
The cell solution was then diluted to contain 1000 cells/mL.  Spheroids were formed by 
pipetting cells onto a 1.5% (wt/vol) agarose coated 96-well plate for 72 hours with 2.5% 
(vol/vol) of Matrigel (Corning) added to the media and cell suspension.  The cell 
suspension with Matrigel added was poured into a basin and pipetted into the agarose 
coated 96 well plate using a multi-channel pipette.  After 72 hours on agarose, the cells 
aggregated into 3D compact multicellular spheroids.  
4.2.8 Spheroid Embedding   
100 cell spheroids were not visible by eye and could not be consistently obtained 
from the well for embedding.  Wells in the 96 well plate containing well-formed 
spheroids were marked by observing under a 10x light microscope.  The media and 
spheroid from several wells were pipetted into an Eppendorf tube and spun down briefly 
in a centrifuge.  5uL aliquots of the media and spheroid solution were pipetted into wells 
of a 24 glass bottom plate.  The wells were then observed under the microscope and wells 
containing spheroids were marked.  Media in the wells not containing spheroids were 
pipetted out and only wells containing spheroids were kept. The process was repeated 
until the desired number of spheroids was collected.  Collagen at the desired 
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concentration was pipetted into the well containing the spheroids and mixed well.  
Fluorescent MitoTracker dye (Life Technologies) was incubated with the cells for 24 
hours.  
4.2.9 Spheroid Microrheology   
The location of the spheroid within the collagen gel was first determined on the 
confocal microscope using the 10x objective.  A bright field image of the spheroid at 10x 
was taken to capture the structure of the entire spheroid.  Then, images of the edge and 
core of the spheroid were taken at 63x.  The edge of the spheroid was determined by 
finding the spheroid-collagen interface.  Four images of the edge were taken around the 
perimeter of the spheroid (Figure 4-17).  Images of the core were taken in the 
approximate center of the spheroid and as high as the working distance of the 63x 
objective would allow, approximately 50 !M.  Several cells in the field of view were 
tracked for 100 seconds at 50 ms per frame using a confocal microscope.  A schematic of 
spheroid imaging regions is shown in Figure 4-17. 
4.2.10 Spheroid Data Analysis.    
Imaris software (Bitplane) was used to trace the displacement vs. time curve for 
the edge and core cells.  Only the very outer layer of cells on the edge of the spheroid 
were analyzed as edge cells.  Cells in the core were classified as cells within the center 
not touching the edge in the field of view.  A schematic of spheroid data analysis regions 
is shown in Figure 4-17.  The data were then analyzed in MatLab as previously 
described151.  The mean-squared displacements (MSDs) were calculated and net 
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displacements were subtracted for each tracer to account for drift and persistent motions.  
The standard error of the mean (s.e.m.) was used to determine the error bars.  
 
4.3 Results  
4.3.1 Single Cell Microrheology in 1-4mg/mL collagen 
 Using mitochondria-tracking microrheology, we tracked the trajectories of 
fluorescently labelled mitochondria in cells embedded within a 3D collagen matrix and 
determined the mean-square displacements.  At early time scales, low and flat MSDs 
indicate stiffer, solid materials.  At longer time scales, MSDs with a large slope indicate 
more fluid-like intracellular motor-driven activity151,153.  The exponent β, the logarithmic 
slope calculated from the MSD, indicates the power-law time interval dependence of the 
MSDs151.  The β values describe the type of motion in the intracellular environment with 
a β close to 0 corresponding to constrained motions and a β close to 1 corresponding to 
diffusive motions155,156.  However, the internal environment of a cell is a non-equilibrium 
system with motions beyond thermal fluctuations due to molecular motor activity 
resulting in additional internal stress fluctuations.  As a result, the MSDs and β’s increase 
at relatively longer time scales due to the cellular motor driven activity151,152.  Based on 
this, we can use MSD data at short time scales to characterize cellular stiffness and longer 
time scale data to interpret intracellular motor activity.  
 From our particle tracking experiments, we found that the MSD was altered by 
changes in the collagen concentration, which in turn affected the stiffness and motor-
driven activity of cells.  In the untreated condition (Figure 4-4c), the MSD decreased with 
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increasing collagen concentration at shorter time scales.  The decrease in MSD indicated 
that cellular stiffness increased with an increase in the collagen concentration.  At longer 
time scales, the increase in cellular stress fluctuations due to motor activity led to an 
increase in active internal fluctuation and higher β values.  The β increased for the 
untreated cells from 1 mg/mL to 4 mg/mL (Figure 4-4d).  The increase in β indicated that 
cells have higher motor-driven activity with increasing collagen concentration.  
 
4.3.2 Drug Treated Single Cell Microrheology in 1-4mg/mL Collagen  
 The influence of collagen concentration on intracellular activity and drug 
response is not well understood because studies that use 3D in vitro models do not 
commonly incorporate the varying density of the ECM in different parts of the body or 
with disease development100,116,157.  To study the intracellular activity with drug 
treatment, the changes in MSD and β can be compared to the untreated condition.  In this 
section, we studied how disrupting cellular processes affected the intracellular mechanics 
of cells embedded in collagen.  We applied GM6001, Y27632, and Paclitaxel and 
measured the resulting cellular fluctuations.  
 Matrix metalloproteinases allow for cells to migrate through a collagen rich ECM, 
cleave collagen, and remodel the ECM.   GM6001, a broad spectrum MMP inhibitor, was 
utilized to study how inhibition of MMPs affect intracellular activity in various collagen 
concentrations158.  The MSD decreased with increasing collagen concentration at shorter 
time scales (Figure 4-5a).  The β increased with increasing collagen concentration at 
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longer time scales (Figure 4-5d).  Previous studies of cells treated with GM6001 have 
shown an increase in leading edge kinetics and force generation as cells attempt to 
migrate in a ECM, which may explain the increase in motor activity observed in the 
denser matrices158,159. 
 In addition to MMPs, cell migration involves cytoskeleton associated functions 
regulated by Rho-associated protein kinase (ROCK), including actin filament structuring 
and cell contraction160.  The drug Y27632 was used to inhibit ROCK and study the 
impact of cytoskeletal activity on intracellular activity.  Y27632 inhibits myosin light 
chain phosphorylation by binding to the catalytic site of ROCK161.  The MSDs increased 
with increasing collagen concentration for 1-3 mg/mL and decreased at 4 mg/mL (Figure 
4-5b).  Lower β at longer time scales compared to the untreated condition indicated 
reduced motor-driven activity.   
To further study the impact of collagen concentration on the motor-driven 
fluctuations, cells were treated with blebbistatin.  Blebbistatin, which inhibits myosin II 
motor activity downstream of ROCK, was used to confirm the influence of myosin II in 
the mechanical properties of the cells162.  With blebbistatin treatment, the MSD increased 
at short time scales indicating that cell stiffness was reduced compared to untreated cells 
(Figure 4-7).  No clear trend was observed in the MSD and β curves of blebbistatin 
treated cells as a function of matrix concentration. 
  Collagen concentration has been shown to be increased in aggressive breast 
cancer55,138.  To study the impact of varying collagen concentration on drug response, we 
test a common chemotherapeutic agent, Paclitaxel.  Paclitaxel stabilizes microtubules, 
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which in turn reduces depolymerization and dynamics124,163.  The MSD for cells treated 
with Paclitaxel decreased with increasing collagen concentration for 1-3 mg/mL (Figure 
4-5c).  β was lower than that of the untreated condition at longer time scales.  Due to 
microtubule stabilization, Paclitaxel treatment may reduce motor-driven activity and thus 
reduce active cytoskeletal behavior.  
 With the drug treatment studies, we found that the mechanical response of cells to 
cytoskeletal drug treatments was dependent on collagen concentration.  Figure 4-8 shows 
a comparison of the MSD and β curves of the untreated and various drug treated 
conditions.  
 
4.3.3 Fundamental Physical Properties of the Intracellular Environment 
 To determine the fundamental physical properties from the MSDs, the power 
output and the intracellular shear modulus were calculated by performing a nonlinear 
least squares fitting of the MSDs to the model described in Mak et al (2017):  
"#$ % = '()*%+3-./ 1 + 2 × 1 + 4'()* × %2 + 1  
 
N is the dimensionality, () is the Boltzmann constant, T is the temperature, t is the time 
interval, r is the radius of the tracer particle (i.e. the mitochondria), 2 is the exponent 
characterizing the power-law frequency dependence of the shear modulus, B is the 
coefficient of the shear modulus, and A is the average instantaneous power output on the 
tracers generated by molecular motors.  Figure 4-9 shows the normalized A and B values 
for each condition.   
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 The molecular motor output A increased for the untreated condition from 1-3 
mg/mL collagen concentration.  Similarly, the molecular motor output increased with 
collagen concentration for the GM6001 condition.  Y27632 and Paclitaxel treatment 
reduced motor power generation A compared to the untreated condition at 2 mg/mL and 
3 mg/mL.  The shear modulus B for the untreated and GM6001 treated conditions 
increased with higher collagen concentration.  The overall shear modulus values for 
Y27632 and Paclitaxel treated conditions were lower than that of the untreated condition.  
In addition to the fundamental parameters, the effective cell stiffness can also be 
determined from the MSD153  (Figure 4-10).  The previously described model 
quantitatively links the measured MSDs to the intracellular material properties and 
motor-driven activity.  The A parameter indicates the instantaneous power output 
generated by molecular motors while the B parameter represents the shear modulus.  The 
shear modulus B can be considered an “effective modulus” that incorporates both the 
cytoskeletal and cytosolic contributions.  
 
4.3.4 Morphological Characteristics of Drug Treated Cells   
  Next, we examined the morphological characteristics of cells with the different 
drug treatments inside a 3D ECM.  We determined the cell area, perimeter, aspect ratio, 
and circularity of Phalloidin stained cells in 2 mg/mL collagen (Figure 4-11).  Images of 
drug treated and untreated cells in 2 mg/mL collagen can be found in Figure 4-12. 
Y27632 treated cells were significantly different from the other conditions for all four 
shape descriptors.  There was no statistical difference between the untreated, GM6001, 
! 67 
and Paclitaxel treated cells.  Cells treated with Y27632 have a larger cell area and 
perimeter than the untreated condition.  The loss of contractile activity with Y27632 
treatment may lead to the cells elongated non circular shape with frequent protrusions164.   
Cell shape factors were also determined for untreated and drug treated cells in 1, 
3, and 4 m g/mL collagen gels (Figure 4-13).  Similar trends were seen in these collagen 
concentrations as was observed in the 2 mg/mL condition.  For example, the Y27632 
treated cells had higher cell areas and perimeters than the other cells.  In addition, the 
Y27632 treated cells also had the lowest circularity and highest aspect ratio.  Previous 
studies have shown that blebbistatin-treated cells exhibit less circular morphologies with 
relatively long protrusions, similar to Y27632 treated cells165,166.  
 
4.3.5 Cancerous and Non-cancerous Cell Microrheology Comparison  
To understand the changes that occur to the intracellular activity and elasticity 
with cancer development, the differences in MSD and β can be compared to a non-
cancerous breast cell line, MCF10A.  As mentioned previously, the MDA-MB-231 cells 
are a triple negative metastatic breast cancer derived from the metastasis of a pleural 
effusion.  In comparison, MCF10A cells are a non-tumorigenic cell line derived from 
benign proliferative breast tissue120.   
 Similar to the MDA-MB-231 results, the MSD decreased with increasing collagen 
concentration for the MCF10A untreated condition.  The MCF10A MSD and β curves of 
the untreated and drug treated cells for 1-4 mg/mL collagen can be found in Figure 4-14.  
In addition, the β increased with increasing collagen concentration from 1-3 mg/mL in 
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the untreated condition.  The same trend was observed in MSDs of the drug treated 
MCF10A cells with an increase in collagen concentration leading to a decrease in the 
MSD.  The β of the paclitaxel treated cells was lower than that of the untreated cells.  The 
MSD and β values for the MCF10A untreated and drug treated cells for 1-4 mg/mL 
collagen are shown in Figure 4-15. 
 We then compared the MSD and β of the MDA-MB-231 cells to those of the 
MCF10A cells (Figure 4-16).  In the untreated condition, the MSD of the MCF10A cells 
was higher than that of the MDA-MB-231 cells.  In contrast, the β of the MDA-MB-231 
cells was higher than that of the MCF10A cells.  Similar trends were observed in the drug 
treated conditions with higher MSD for MCF10A cells and higher β for MDA-MB-231 
cells.  The MSD curves of the MCF10A cells were higher at shorter time scales, but 
flatter at longer time scales, which resulted in lower β values.  The MCF10A cells were 
softer at earlier times scales compared to the MDA-MB-231 cells.  However, at longer 
time scales, the MDA-MB-231 cells had higher intracellular motor activity.   
 
4.3.6 Spheroid Microrheology in 1-4mg/mL Collagen 
 Using the same mitochondria-tracking microrheology method, we tracked the 
trajectories of fluorescently labeled mitochondria in 100 cell spheroids embedded within 
a 3D collagen matrix.  Cells on the outer layer of the spheroid in contact with the 
collagen were considered edge cells (Figure 4-17).  Cells in the middle inner region were 
classified as core cells.  There was no overlap of the core and edge cells in the analysis.   
From our tracking studies, we found that collagen concentration affects the MSD 
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and intracellular activity of cells within the spheroid (Figure 4-18).  For the MDA-MB-
231 spheroids, the core and edge MSD decreased as the collagen concentration increased 
(Figure 4-19).  The core and edge β also increased as the collagen concentration 
increased.  The core MSD was higher than the edge MSD for all collagen concentrations.  
In addition, the edge β was higher than the core β for all collagen concentrations.  
For the MCF10A spheroids, we observed similar trends in the MSD and β as we 
found in the MDA-MB-231 spheroids (Figure 4-20).  The core and edge MSD decreased 
while the β increased as the collagen concentration increased (Figure 4-21).  The core 
MSD was higher than the edge MSD for all collagen concentrations.  The edge β was 
also higher than the core β for 1-4 mg/mL collagen.   
To further investigate the behavior of the cancerous and non-cancerous cells, we 
compared the core and edge MSD and β values (Figure 4-22).  For the MSD, the MDA-
MB-231 cells had lower values than the MCF10A cells in both the core and edge.  The 
higher MSD for the MCF10A edge and core cells indicated that these cells had a lower 
stiffness than the MDA-MB-231 cells.  In contrast, the MDA-MB-231 cells had higher 
core and edge β values than the MCF10A cells for 1-4 mg/mL collagen.  The higher β 
values for the MDA-MB-231 cells indicated that these cells had higher intracellular 
motor activity than the MCF10A cells.  
  
4.4 Discussion 
 The goal of this chapter was to investigate the impact of the 3D 
microenvironment on the intracellular activity of cells.  The 3D embedded single cell and 
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spheroid model provided a more physiologically relevant system that allowed us to study 
both cell-cell and cell-ECM interactions.  Conventional drug research commonly uses the 
results of 2D in vitro studies to predict the outcome in an in vivo system15.  However, the 
forced cell polarization and altered cytoskeletal configuration of a 2D cell cultured on 
hard plastic or glass substrates may not provide results that accurately translate to a 
physiological system100.  
 From our 3D single cell embedded experiments, we found that the intracellular 
MSD of untreated cancerous cells increased with decreasing collagen.  We also observed 
that the active internal fluctuations increased with increasing collagen concentration.  
Drug treated cells were also found to have altered stiffness and motor-driven activity 
dependent on the collagen concentration.  Similar trends were observed in the MSD and β 
of non-cancerous MCF10A cells.  However, the MSD was higher at earlier time scales 
for the MCF10A cells while the β was higher at later time scales for the MDA-MB-231 
cells.  Our results are consistent with a previous study that showed cancer cells exhibiting 
higher motor activity and traction forces compared to non-cancerous cells152,167.  These 
results suggest that the intracellular mechanics and cellular drug response is influenced 
by the concentration of ECM in 3D. 
The mean squared displacements (MSD) were calculated from the trajectories of 
fluorescently labeled mitochondria in cells embedded in a 3D collagen matrix.  The MSD 
characterizes the dynamics of tracked particles, which relate to the mechanical properties 
of the medium.  In the cell, motor activity results in additional internal stress fluctuations 
beyond thermal fluctuations, which lead to an increase in MSDs at relatively longer time 
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scales.  When particles are transported in this nondiffusive manner, MSD becomes 
nonlinear w/time and can be described w/time-dependent power law. Therefore, 
logarithmic time derivative of MSDs was calculated to determine diffusive exponent beta 
(β). β classifies type of motion exhibited in the intracellular environment and allows us to 
extract information about motor driven activities151.  
Measuring MSD and β allows us to determine physical characteristics and 
behavior of cell.  The MSD allows us to interpret the elasticity of the cells with low and 
flat MSDs indicating a stiffer and higher MSDs indicating a more fluid like cell. β allows 
us to interpret the motor driven activity in the cell, with high β indicating more 
intracellular motor driven activity.  Therefore, with mitochondria tracking microrheology, 
we can study how 3D microenvironment affects the dynamic activity of the cytoplasm by 
measuring the MSD and β. This allows us to use short time-scale data to describe 
viscoelastic properties and longer time scale data to interpret information about motor-
driven activities.  Though these results provide a qualitative comparison of the 
intracellular activities, the MSD can be used to determine quantitative fundamental 
physical parameters of the intracellular environment151,153.  
To directly calculate the power output from molecular motor activity and the 
intracellular shear modulus, we performed a nonlinear least squares fitting of the MSDs 
to the model described in Mak (2017)153. Calculating these fundamental parameters of the 
intracellular environment allows us to interpret the MSD and β data to quantitatively 
determine how intracellular mechanics and dynamics change with collagen concentration.  
Normalized A and B values for each condition and collagen concentration are shown in 
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Figure 4-9.  The previously described model provides a quantitative relationship between 
the MSD measured from our experiments and the motor-driven activity and cellular 
material properties.   
 With the particle tracking experiments in the spheroid model, we found that the 
MSD and β of cells in the core and edge were affected by the collagen concentration.   
The higher β of the cells on the spheroid edge indicate a higher intracellular motor 
activity compared to the β of the core cells.  Cells in the edge of the spheroid are directly 
in contact with the matrix and may be involved in several cellular processes such as 
pulling and aligning the collagen fibers of the matrix or migrating into the ECM.  In 
comparison, cells in the core are completely surrounded by other cells and have restricted 
space to migrate or proliferate.  The location of the cells within the spheroid core also 
limits access to nutrients diffusing from the media.  As a result, cells in the spheroid core 
may have lower intracellular activity.  
 In both the spheroid and diffusely embedded single cell model, the β values of the 
MCF10A cells were lower than the β of the MDA-MB-231 cells.  The non-cancerous 
nature of the MCF10A cells may explain the lower β value.  In comparison, the MDA-
MB-231 cells are a highly metastatic and aggressive breast cancer cell type.  As a result, 
these cells are more likely to migrate or invade into the ECM.  The contraction of actin 
filaments by myosin motors within the cytoplasm and the collective activity of these 
motors and active forces may increase the motions within the cytoplasm79,81,82.  Imaging 
and measuring these motions allowed us to directly quantify the intracellular activity and 
the influence of the ECM on it.  
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 The impact of varying collagen concentration on cellular mechanical behavior 
suggests that the 3D ECM influences the intracellular activity and drug response of 
cancerous and non-cancerous breast cells.  Varying the collagen concentration changes 
the density and stiffness of the 3D matrix, which may impact the cell-ECM interactions 
and accordingly the intracellular motor activity.  By incorporating physiologically 
relevant collagen concentrations into our 3D model, we can represent the ECM at 
different stages of tumor progression or distinctive disease microenvironments.  
Therefore, we can expand on previous 2D microrheology work and determine the 
physical characteristics of non-tumorigenic and metastatic cells in representative 3D in 
vivo conditions.  
 The observed trend of the influence of collagen concentration on the intracellular 
mechanics of cells in 3D matrices was disrupted when ROCK, myosin II, and 
microtubules were inhibited.  Some disease processes involve and require 
mechanosensing of the 3D ECM.  By disrupting integral cytoskeletal components, the 
disease progression may be modulated or suppressed, which could provide a 
complementary therapeutic strategy to control tumor behavior.  Studies have indicated 
that the physical and mechanical properties of the environment influence the behavior of 
cells.  For example, substrate stiffness in 2D flat surfaces affects cellular processes such 
as differentiation, invasion, and proliferation168,169.  From our experiments, we found that 
cells in 3D ECMs also experience mechanosensing of the environment, which can be 
disrupted by inhibitors.  
 Because the tumor microenvironment is complex and continually changing, 
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matrix concentration is a key parameter to consider in cancer studies.  With our system 
that integrates 3D embedded single cell diffuse and spheroid models with particle 
tracking microrheology, we can characterize the effect of the matrix mechanics on 
intracellular activity.  This method tracks the fluctuations of particles within the cells 
without requiring direct contact or perturbation.  In addition, the collagen concentration 
can be adjusted to better represent in vivo conditions.  Therefore, characterizing the 
relationship between the cells and matrix in 3D may provide a deeper understanding of 
how the microenvironment influences the intracellular activity of the cytoplasm in 
healthy and disease conditions. 
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Figure 4-1: ECM Stiffness Influences the Mechanical Properties of the Cell 
Schematic showing an overview of factors studied in this section (circled in blue).  The 
mechanical effect of the ECM density on a cell embedded within a 3D matrix can be 
determined by measuring the cellular stiffness and motor-driven activity.  
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Figure 4-2: Overview of Mitochondria-Tracking Microrheology 
a) Cells are embedded into varying collagen concentrations for 24 hours and incubated 
with MitoTracker for 1 hour. Image acquisition performed on cells with confocal 
microscope. b) Imaris software used to trace the displacement vs. time curve for each 
tracer and the mean-squared displacements are calculated.  
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Figure 4-3: Fluorescent Mitochondria of Untreated Cells in 1-4 mg/mL Collagen 
Images of brightfield and mCherry of a-b) Cell in 1 mg/mL collagen c-d) Cell in 2 
mg/mL collagen e-f) Cell in 3 mg/mL collagen and g-h) Cell in 4 mg/mL collagen. Scale 
bar is 10 µm. 
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Figure 4-4: MSD and β of MDA-MB-231 Cells in 3D Collagen 
a) MSD curves of MDA-MB-231 cells in 1-4 mg/mL collagen. b) Beta curves of MDA-
MB-231 cells in 1-4 mg/mL collagen. c) Comparison of MSDs at 50 ms with varying 
collagen densities (1-4 mg/mL) d) Comparison of β’s at t = 1 s with varying collagen 
densities. Error bars are s.e.m. * indicates p<0.05.  Color code of the curves and bar 
graph are the same as in Figure 4-4a and Figure 4-4c. 
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Figure 4-5: MSD and β of MDA-MB-231 Cells With Different Drug Treatments 
MSD curves of MDA-MB-231 cells treated with a) GM6001 b) Y27632 and c) Paclitaxel in 1-4 mg/mL collagen.  Beta curves 
of MDA-MB-231 cells treated with d) GM6001 e) Y27632 and f) Paclitaxel. g) Comparison of β’s at t = 1 s with varying drug 
treatments. Error bars are s.e.m. * indicates p<0.05. Color code of the curves is the same as in Figure 4-5a. 
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Figure 4-6: Effect of DMSO on the Microrheology of Cells 
a) MSD curves of MDA-MB-231 cells treated with DMSO and control cells embedded in 1 mg/mL collagen. b) β curves of 
MDA-MB-231 cells treated with DMSO and control cells embedded in 1 mg/mL collagen. c) MSD curves of MDA-MB-231 
cells treated with DMSO and control cells embedded in 2 mg/mL collagen. d) β curves of MDA-MB-231 cells treated with 
DMSO and control cells embedded in 2 mg/mL collagen e) MSD curves of MDA-MB-231 cells treated with DMSO and 
control cells embedded in 3 mg/mL collagen. f) β curves of MDA-MB-231 cells treated with DMSO and control cells 
embedded in 3 mg/mL collagen g) MSD curves of MDA-MB-231 cells treated with DMSO and control cells embedded in 4 
mg/mL collagen. h) β curves of MDA-MB-231 cells treated with DMSO and control cells embedded in 4 mg/mL collagen. 
Error bars are s.e.m. 
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Figure 4-7: Blebbistatin Treatment of Cells  
Cells were incubated with 50 µM of blebbistatin for 2 hours in 1-4 mg/mL collagen gels. a) MSD curves and b) β curves of of 
MDA-MB-231 cells treated with blebbistatin embedded in 1-4 mg/mL collagen. Error bars are s.e.m.   
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Figure 4-8: Comparison of Drug Treated and Untreated Cells 
a) Comparison of MSDs at t = 50 ms and b) Comparison of β at t = 1 s of untreated and drug treated cells in 1-4 mg/mL 
collagen. Error bars are s.e.m. * indicates p<0.05.!!!!
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Figure 4-9: Fundamental Parameters of the Intracellular Environment 
a) A is the power generated by the molecular motors. b) B is the shear modulus coefficient. Values are normalized to untreated 
1 mg/mL collagen.  
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Figure 4-10: Motor Driven Activity and Effective Cell Stiffness 
a) Power output generated by molecular motors and b) Shear modulus of cells embedded in 1-4 mg/mL collagen. Assumed 
mitochondria with radius rtracer = 70 nm. 
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Figure 4-11: Analysis of Untreated and Drug Treated Cells in 2 mg/mL Collagen 
a) Cell area b) Perimeter c) Aspect Ratio, and d) Circularity of untreated cells (n = 21), 
GM6001 treated cells (n = 22), Y27632 treated cells (n = 22), and Paclitaxel treated cells 
(n = 23) with phalloidin stain. Error bars are s.e.m. * indicates p<0.05.  
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Figure 4-12: Images of Drug Treated and Untreated cells in 2 mg/mL collagen 
a-h) Bright field and fluorescence images of (a,b) untreated cells (c,d) GM6001 treated 
cells (e,f) Y27632 treated cells and (g,h) Paclitaxel treated cells with phalloidin stain. 
Green represents actin. The scale bar is 20 µm.  
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Figure 4-13: Cell Morphology Analysis of Untreated and Drug Treated Cells  
a) Cell area b) Cell perimeter c) Aspect ratio, and d) Circularity of phalloidin stained 
cells. Number of cells for untreated (1 mg/mL n=15, 2 mg/mL n=21, 3 mg/mL=15, 4 
mg/mL n=15), GM6001 treated cells (1 mg/mL n=14, 2 mg/mL n=22, 3 mg/mL n=15, 4 
mg/mL n=15), Y27632 treated cells (1 mg/mL n=15, 2 mg/mL n=22, 3 mg/mL n=15, 4 
mg/mL n=14), and Paclitaxel treated cells (1 mg/mL n=15, 2 mg/mL n=23, 3 mg/mL 
n=15, 4 mg/mL n=15). Error bars are s.e.m. 
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Figure 4-14:  MSD and β of MCF10A Untreated and Drug Treated Cells  
MSD and β of (a,b) untreated, (c,d) GM6001 treated,  (e,f) Y27632 treated, and (g,h) 
Paclitaxel treated MCF10A cells in 1-4 mg/mL collagen. Error bars are s.e.m. 
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Figure 4-15: MSD and β of Drug Treated and Untreated MCF10A Cells 
a) Comparison of MSDs at t = 50 ms and b) Comparison of β at t = 1 s of untreated and 
drug treated MCF10A cells in 1-4 mg/mL collagen. Error bars are s.e.m. !
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Figure 4-16: Comparison of MSD and β of MDA-MB-231 and MCF10A Drug 
Treated and Untreated Cells 
Comparison of MSD and β of (a,b) untreated, (c,d) GM6001 treated,  (e,f) Y27632 
treated, and (g,h) Paclitaxel treated MDA-MB-231 and MCF10A cells in 1-4 mg/mL 
collagen. Error bars are s.e.m. 
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Figure 4-17: Overview of Spheroid Microrheology 
a) The spheroid that forms after incubation on agarose for 72 hours is embedded into 
collagen. Mitotracker is added to the collagen + spheroid sample and imaged b) View of 
the spheroid core (blue) and spheroid edge (purple)  
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Figure 4-18: MSD and β of MDA-MB-231 Spheroid Core and Edge 
MSD and β of core and edge regions for MDA-MB-231 spheroids embedded in a,b) 1 
mg/mL c,d) 2 mg/mL e,f) 3 mg/mL and g,h) 4 mg/mL. Error bars are s.e.m.    
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Figure 4-19: Comparison of MSD and β of MDA-MB-231 Spheroid Core and Edge 
a,b) The MDA-MB-231 spheroid core MSD and β c,d) MDA-MB-231 spheroid edge 
MSD and β and e,f) MSD and β values for MDA-MB-231 spheroids embedded in 1-4 
mg/mL collagen. Error bars are s.e.m.   
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Figure 4-20: MSD and β of MCF10A Spheroid Core and Edge 
MSD and β of core and edge for MCF10A spheroids embedded in a,b) 1 mg/mL c,d) 2 
mg/mL e,f) 3 mg/mL and g,h) 4 mg/mL. Error bars are s.e.m.    
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Figure 4-21: Comparison of MSD and β of MCF10A Spheroid Core and Edge 
a,b) The MCF10A spheroid core MSD and β c,d) MCF10A spheroid edge MSD and β 
and e,f) MSD and β values for MCF10A spheroids embedded in 1-4 mg/mL collagen. 
Error bars are s.e.m. 
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Figure 4-22: Comparison of MSD and β of MDA-MB-231 and MCF10A Spheroid 
Edge and Core 
Comparison MCF10A and MDA-MB-231 spheroid a) Core MSD b) Core β c) Edge 
MSD and d) Edge β. Error bars are s.e.m. 
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CHAPTER 5. Investigation of YAP/TAZ activity in spheroid model 
 
5.1 Introduction 
 Utilizing 3D in vitro systems provide a wealth of information that is not present in 
2D samples102.  For example, with 3D tumor spheroids embedded into a matrix, the cell-
cell, cell-ECM, cellular heterogeneity, and collective behavior can be studied.  In 
addition, information about the tissue structure, mechanical cues, and biochemical 
signaling, and various cellular structures can be obtained.  
Image acquisition of 3D samples is possible with systems that allow for 3D 
optical sectioning, such as confocal and multi-photon microscopes.  However, due to 
light scattering obscuring the image, visualizing more than a few layers into the sample 
becomes difficult170,171.  Light scattering can be caused by several cellular components 
including cellular membranes, myelin, and lipid droplets172.  A common method for 
visualizing 3D samples is to thinly section sample several times.  Unfortunately, the 
method may lead to damage or distortion of individual sections and lead to an incorrect 
volumetric image.  Sectioning also may not provide the full 3D context for the sample, 
such as for imaging neurons with very thin diameters that extend and branch in many 
directions113.  
To reduce or alter light scattering within thick samples, tissue clearing techniques 
can be applied.  All tissue clearing techniques equalize the refractive index throughout 
the sample to reduce light scattering.  However, several methods that involve solvent 
based or aqueous based clearing have been developed173.  For example, the CUBIC 
method involves incubation with components such as urea and Triton X-100 to remove 
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lipids and optically clear the sample115.  With cleared tissue samples, the penetration 
limits due to light scatter are removed and imaging deeper into the sample is possible113.   
In normal tissues, the YAP/YAZ signaling pathway has been shown to be 
involved in regulating cellular growth and homeostasis174.  When YAP and TAZ are 
activated, they translocate to the nucleus and can induce proliferation and stem cell 
characteristics.  If YAP and TAZ are phosphorylated by kinases LATS1/2, they are 
prevented from translocating to the nucleus and are instead remain the cytoplasm18.  
 YAP/TAZ signaling has also been shown to be upregulated in aggressive, high 
grade tumors93.  In addition, clinical data showed elevated expression of YAP/TAZ was 
linked to metastasis and chemoresistance.  The high YAP/TAZ activation in cancer may 
be a result of external mechanical cues such as the increase in responsiveness of the cell 
to ECM stiffening and aberrant multicellular architecture175,176.  To determine whether 
the altered ECM associated with cancer progression increases YAP/TAZ signaling, the 
mechanical and molecular relationship between the cancer cells and ECM must be 
understood.  
 In this chapter, we investigated the interaction between the ECM and YAP/TAZ 
activity within a 3D matrix (Figure 5-1).  To study the mechanisms leading to YAP/YAZ 
upregulation in cancer, we integrated our 3D in vitro embedded spheroid model with 
tissue clearing.  This system allowed us to investigate ECM mechanosensing and cell-cell 
contact sensing within a physiologically relevant 3D matrix.  We measured the 
YAP/TAZ nuclear fraction in 3D spheroids composed of two cells lines, the non-
cancerous MCF10A cells and the breast cancer MDA-MB-231 cells.  In addition to being 
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able to visualize and quantify the YAP/TAZ activity spatially, we were able to 
characterize the activity temporally using our discrete invading spheroid model.  
Therefore, with this approach, we can investigate how tumor progression, cell type, and 
ECM concentration influence YAP/TAZ activity.  
 
 
5.2 Materials and Methods 
5.2.1 Cell Culture   
The metastatic breast adenocarcinoma cell line MDA-MB-231 (ATCC) was 
maintained in tissue culture treated flasks and kept in an incubator at 37˚C, 5% CO2, and 
75% humidity.  The MDA-MB-231 cells were cultured in DMEM (Dulbecco's Modified 
Eagle Medium, Life Technologies) supplemented with 10% fetal bovine serum (ATCC) 
and 1% (v/v) penicillin-streptomycin (ATCC), in accordance with manufacturer 
recommendations.  MCF10A was cultured in Growth Media according to a previously 
published protocol120. 
5.2.2 Large Spheroid Formulation   
Cells were trypsinized from a cell culture flask and counted on a hemocytometer.  
The cell solution was then diluted to contain 100,000 cells/mL or 10,000 cells/mL.  
Spheroids were formed by pipetting cells onto a low attachment round bottom 96-well 
plate with 2.5% (vol/vol) of Matrigel (Corning) added to the media and cell suspension.  
The cell suspension with Matrigel added was poured into a basin and 0.1 mL was 
pipetted into the low attachment round bottom 96 well plate using a multi-channel 
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pipette.  After 48 hours of incubation, the cells aggregated into compact 3D multicellular 
spheroids.  
5.2.3 Large Spheroid Embedding   
The 10,000 and 1000 cell spheroids were visible by eye and could be directly 
pipetted from the round bottom 96 well plate for collagen embedding.  Wells in the 96 
well plate containing well-formed spheroids were marked by observing the spheroids 
with a 10x light microscope.  A 200 uL pipette tip was used to pipette up the spheroid in 
a total volume of 10 uL.  The spheroid and media were transferred to the center of the 
glass bottom well plate.  Collagen at the desired concentration was pipetted into the well 
containing the spheroids and mixed with a pipette tip to ensure the spheroid was 
incorporated into the unpolymerized collagen.  The plate was flipped every two minutes 
for 10 minutes to ensure that the spheroid did not sink to the bottom of the well.  Media 
was added to the collagen after 1 hour.  
5.2.4 CUBIC Clearing of Spheroids 
To visualize a dense multicellular spheroid, CUBIC (Clear unobstructed brain 
imaging cocktails)115 tissue clearing was adapted to a embedded spheroid 3D in vitro 
model to make the structure optically clear.  We formed the spheroid and embedded it 
into a collagen gel, as previously described in 5.2.3.  Then, we fixed the spheroid and 
collagen with 4% paraformaldehyde in PBS (Thermo Fisher).  After 18-20 hours, we 
washed out the PFA with PBS and immersed the spheroid and collagen in ½ reagent-1.  
After 4-6 hours, we immersed the spheroid and collagen in reagent-1 for 24 hours and 
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refreshed reagent-1 every 48 hours.  The well plate containing the samples and clearing 
reagent was placed on a rocker at room temperature at the highest speed setting.  DAPI 
nuclear stain (Sigma Aldrich) was added to reagent-1 at a concentration of 2!"M.  DAPI 
and reagent-1 were refreshed every 48 hours for a total of 6 days.  An overview of the 
procedure is shown in Figure 5-2. 
5.2.5 Discrete Invasion Dynamics  
Spheroids were fixed at different time points to observe discrete snapshots of 
invasion into the collagen matrix.  Spheroids were embedded into collagen as previously 
described and immediately fixed (0h), or fixed at 24, 48, or 72 hours after embedding.  
The samples to be fixed at later time points were kept in the incubator at 37˚C, 5% CO2, 
and 75% humidity until the desired time point.  This method allowed us to use a larger 
spheroid size and longer imaging times compared with live imaging of spheroids.  In 
addition, the ability to fix at any time point allowed us to study discrete temporal 
characteristics of the spheroid as it invaded into the collagen gel.  A schematic of the 
process is shown in Figure 5-6.  
5.2.6 Imaging of Cleared Spheroids  
Fixed and cleared spheroids were imaged using an Ultima Investigator 
multiphoton microscope (Bruker, Billerica, MA) equipped with a 16X (0.80 N.A.) water 
immersion lens (Thorlabs, Newton, NJ).  A titanium-sapphire laser was tuned to 1050 nm 
for multiphoton excitation of both DAPI and YAP/TAZ.  Laser power was controlled 
using a pockels cell, while emitted photons were detected using PMTs.  We used a pixel 
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dwell time of 10 µs and an image size of 1024 x1024 pixels (equivalent to 824.6 x 
824.6 µm2). A 663 to 738 nm bandpass filter isolated YAP/TAZ (Channel 1) 
fluorescence, while a 490 to 560 nm bandpass filter isolated DAPI fluorescence (Channel 
2).  Image stacks were acquired every 5 µm to capture the entire spheroid. Images were 
acquired by Dr. Jacopo Ferruzi.  
5.2.7 Data Analysis of Cleared Spheroids 
The reference point in the center of the spheroid was set using the “Add new 
reference frame” function.  Spheroids were analyzed with Imaris using the Cell Module. 
Nuclei were detected using the “cytoplasm as a boundary” selection with the DAPI stain 
channel.  Touching cells were split and the automatic cell threshold (absolute intensity) 
was used.  The automatic value for the cell seed points and cell number of voxels were 
used.  
The top and bottom 1% of nuclei volume were discarded to account for under 
segmentation and over segmentation of the nuclei.  The nuclei volume was ordered based 
on distance of the nuclei from the center reference point.  The core cells were classified 
as 0 µm to 75 µm from the center reference point.  The middle cells were classified as 76 
µm to 125 µm from the center reference point.  The edge cells were classified as 126 µm 
to the furthest point from the center reference point, approximately 200 µm for day 0 
spheroids.  A schematic of the spheroid nuclei regions and reference point is shown in 
Figure 5-9.  
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5.2.8 Immunofluorescence Staining  
For YAP/TAZ staining of single cells embedded within collagen, cells were 
incubated for 24 hours after embedding into collagen. Then, cells were fixed with 4% 
PFA in PBS for 1 hour and permeabilized with 0.1% Triton X-100 for 1 hour at room 
temperature.  Samples were then blocked with 5% donkey serum (Fisher Scientific) in 
0.1% Triton X-100 for 4 hours.  Following blocking, samples were incubated with the 
primary rabbit YAP/TAZ antibody (Cell Signaling Technologies) diluted 1:200 in 5% 
donkey serum 0.1% Triton X-100 for 8 hours at room temperature on a rocker.  Then, 
samples were incubated with Alexa Fluor 647 conjugated donkey anti-rabbit secondary 
antibody (Fisher Scientific) diluted 1:500 in 5% donkey serum 0.1% Triton X-100 for 1 
hour on a rocker at room temperature in the dark.  DAPI nuclear stain (Sigma Aldrich) 
was added with the secondary antibody at a concentration of 1 "M. 
For YAP/TAZ staining of spheroids embedded within collagen, CUBIC clearing 
was performed for 6 days on the sample.  Because the CUBIC process involves both 
fixing and permeabilization, samples were then blocked with 5% donkey serum in 0.1% 
Triton X-100 for 8 hours after the completion of clearing.  Following blocking, samples 
were incubated with the primary YAP/TAZ antibody diluted 1:200 in 5% donkey serum 
0.1% Triton X-100 for 16 hours at room temperature on a rocker.  Then, samples were 
incubated with Alexa Fluor 594 or 647 conjugated secondary antibody diluted 1:500 in 
5% donkey serum 0.1% Triton X-100 for 2 hours on a rocker at room temperature in the 
dark.  DAPI nuclear stain (Sigma Aldrich) was added to reagent-1 during the clearing 
process at a concentration of 2 "M as previously described.   
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5.2.9 YAP/TAZ 3D Embedded Single Cell Segmentation 
 Single cells embedded within 3D gels were analyzed using a custom CellProfiler 
pipeline.  Maximum intensity projections of the nuclei and YAP/TAZ images were found 
using ImageJ.  The nuclei were identified using IdentifyPrimaryObjects and objects 
touching the border image or outside the diameter range were discarded (Figure 5-14).  
The image intensity of the nuclei was measured using MeasureImageIntensity.  Then, the 
YAP/TAZ image was masked using the nuclei identified in the previous step to 
determine the nuclear YAP/TAZ.  The YAP/TAZ signal in the nucleus was measured 
using MeasureImageIntensity using the nuclei as a mask (Figure 5-14).  The YAP/TAZ 
signal in the cytoplasm was measured using the nuclei as an inverted mask.  The nuclear 
to cytosolic YAP/TAZ intensity ratio could then be calculated using the integrated 
intensity values.  
 
5.2.10 YAP/TAZ Spheroid Data Analysis 
To determine the nuclear to cytosolic YAP/TAZ ratio, Imaris Coloc was used to 
calculate the colocalization of YAP/TAZ with the DAPI stain in the nucleus and the 
amount of cytoplasmic stain.  Imaris Coloc can quantify diffuse signals by measuring the 
channel intensity and voxel volume of the entire image.  Accordingly, the spheroid was 
divided into the core and edge regions and analyzed to obtain spatial information of 
YAP/TAZ activity. 
The 2D middle slice of the z-stack was divided into core only (0-75 µm from 
center reference point) and edge only (126 µm from center reference point to furthest 
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point) with representative images shown in Figure 5-20.  The 2D middle slice provided 
information about the core of the spheroid in addition to the edge.  The nuclei were used 
to create a mask in order to determine the amount of YAP/TAZ signal within this region.  
The Imaris Coloc automatic thresholding system was used to remove user bias and the 
colocalization of the 2 channels was measured.  The automatic thresholding algorithm177 
determines the probability of having non-random co-localization and excludes intensity 
pairs that exhibit no correlation.  
From the colocalization of the YAP/TAZ and nuclear signal, the amount of 
nuclear YAP/TAZ was determined.  Imaris Coloc provided several statistics including % 
ROI colocalized, % volume of channel A over threshold value colocalized, and Pearson’s 
coefficient. The % volume of channel A over threshold colocalized value was used to 
calculate the total YAP/TAZ voxel volume.  From the total YAP/TAZ voxel volume, the 
cytoplasmic and nuclear YAP/TAZ voxel volume was calculated.  Then the nuclear to 
cytosolic YAP/TAZ ratio was calculated to determine the amount of activity within these 
regions.  The voxels that met the selection criteria were identified as colocalized regions 
and displayed as a separate image (Figure 5-21).   
 
 
5.3 Results  
5.3.1 CUBIC Clearing Integration with 3D Embedded Spheroid Model  
   To test the feasibility of integrating the CUBIC clearing method with our 3D 
embedded spheroid model, we embedded 10,000 cell MDA-MB-231 spheroids into 2 
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mg/mL collagen.  The original protocol for CUBIC clearing was tailored to a mouse 
organ model, so modifications were made to determine appropriate incubation time for 
full clearing of the sample.  The mouse brain, though larger than our spheroid sample, 
contained a higher lipid content, making it optimal for CUBIC clearing178.  In contrast, 
the spheroid sample had a much lower lipid content179, making it more difficult to make 
the sample completely clear.  
 Spheroid samples were immersed in reagent-1 and imaged over 48 hours in 
brightfield to assess the extent of clearing (Figure 5-3).  The CUBIC cleared spheroids 
were visually much clearer after 48 hours compared to the untreated spheroids.  In 
addition, the collagen gels became visually clearer after 48 hours of CUBIC clearing 
(Figure 5-4).  The control spheroids remained dark and light impenetrable over the 48 
hours.  The uncleared collagen gels were opaque and the spheroid was visible as a small 
white dot.  Though the spheroid and collagen gel appeared to be clearer, the extent of 
clearing needed to be determined to establish the appropriate required clearing time.       
 Spheroid samples were cleared for 2 to 7 days and the nuclei were DAPI stained 
to allow for visualization into the spheroid.  Spheroids cleared for 6 days were found to 
be entirely cleared, which indicated that cells within the core and throughout the spheroid 
could be fully imaged.  Comparison of an uncleared and a day 6 cleared 10,000 cell 
spheroids at the same z-slice position is shown in Figure 5-5.  Only cells on the very 
outer layer of the uncleared spheroid could be imaged, while cells deep within the core of 
the spheroid could be imaged in the cleared spheroids.   
Though we could see the core cells in the cleared spheroid, the limitation of light 
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diffusion versus stain diffusion was not definite.  Was the CUBIC method allowing for 
better diffusion of the DAPI stain into the core, or was the CUBIC method actually 
“clearing” the sample and allowing for light to reach the core of the spheroid?  To answer 
this question, we formed spheroids using cells that were inherently fluorescent.  The 
MDA-MB-231 LifeAct GFP spheroids would allow for imaging of the cells without the 
use of a fluorescent stain.  We imaged 10,000 cells uncleared and cleared spheroids 
formed with these cells and found that the uncleared spheroid still could not be fully 
visualized.  In contrast, we were able to see the cells within the core of the cleared 
spheroid (Figure 5-7).  With our CUBIC clearing and 3D embedded spheroid system 
established, we investigated the ability of our system to study invasion dynamics of the 
spheroid.  
 
5.3.2 Discrete Invasion Dynamics of Spheroid  
 To study the dynamics of cancer progression, changes to the spheroid structure 
and invasion of the cells into the collagen matrix need to be characterized.  Though we 
are required to fix our sample for the clearing procedure, we are able to observe discrete 
temporal snapshots of spheroid invasion.  Due to the limited field of view of the 
microscope, 1000 cell spheroids were used for the discrete invasion dynamic study.  This 
allowed us to simultaneously image cells that had migrated away from the spheroid into 
the matrix in addition to the main spheroid structure.  
 Several spheroids were embedded into collagen in separate wells and either 
immediately fixed after 1 hour or allowed to further incubate.  The spheroids were 
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formed from the same group and the collagen solution was prepared identically for all 
samples.  Spheroids were also fixed at 24 and 48 hours after initial seeding to compare to 
the 0 h condition.  After fixation, spheroids were cleared for 6 days using the previously 
described protocol.  
 With our system, invasion of the cells into the matrix and changes to the spheroid 
bulk structure could be imaged.  Cleared spheroids fixed at day 0, day 1, and day 2 are 
shown in Figure 5-8.  Formation of protrusions into the matrix in day 1 and day 2 
spheroids are visible.  With the ability to visualize entire spheroid structures and invasion 
dynamics, we next investigated the effect of matrix concentration and cell type on 
cellular behavior.    
 
5.3.3 Quantification of Spheroid Nuclei in 3D  
 Nuclei were identified in Imaris using the previously described protocol and the 
volumes were calculated.  The nuclei volume was ordered based on distance from the 
spheroid center reference point and organized into core, middle, and edge regions.  First, 
MDA-MB-231 and MCF10A spheroids embedded in 2 mg/mL in 4 mg/mL collagen at 
day 0 were compared.  
 The nuclei volume in the core, middle, and edge regions were not significantly 
different for all conditions (Figure 5-10).  The core nuclei were slightly higher in the 2 
mg/mL condition than the other regions for both cell types, but not significantly different.  
In contrast, the core nuclei were slightly lower but not significantly different in the 4 
mg/mL condition than the other regions for both cell types.  The middle and edge region 
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nuclei volumes were not significantly different.  The nuclei volumes for the MDA-MB-
231 and MCF10A spheroids in the 2 mg/mL condition were significantly different from 
that of the 4 mg/mL condition for all three regions.  The MCF10A nuclei volumes were 
also found to be generally lower than the corresponding MDA-MB-231 nuclei volumes 
for both 2 mg/mL and 4 mg/mL and within all three regions.  
 Next, we compared the nuclei volume at day 0 and day 2 for MDA-MB-231 
spheroids embedded in 2 mg/mL and 4 mg/mL collagen.  Spheroids fixed at day 2 were 
incubated in the collagen matrix for 48 hours before fixing.  Several large protrusions 
were visible indicating that cells had migrated from the spheroid bulk into the collagen 
matrix.  The nuclei volumes at Day 2 were lower than the nuclei volumes at Day 0 for all 
three regions and both collagen concentrations.  The lower nuclei volume for Day 0 
spheroids embedded in 4 mg/mL compared to the 2 mg/mL condition was also observed 
in the Day 2 spheroids embedded in 4 mg/mL.   
 
5.3.4 YAP/TAZ expression in single cells 
 Most YAP/TAZ staining is performed in 2D with cells on glass or polyacrylamide 
substrates or with thin tissue sections86,92,94,180.  The 2D system can capture some cell-cell 
interactions, but cells are only in contact with each other in one dimension and have an 
unnatural morphology.  In addition, cell-ECM interactions are not usually studied in a 
full 3D context.  To verify that YAP/TAZ activity could be visualized in our 3D spheroid 
model, we first tested the immunofluorescence in the 3D single cell embedded model.   
MDA-MB-231 cells were embedded into 2 mg/mL and 4 mg/mL collagen gels for 
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24 hours and fixed.  The immunofluorescence staining protocol as described previously 
was followed.  From our results, we found that YAP/TAZ signal could be imaged and 
quantified using a custom CellProfiler pipeline (Figure 5-13).  The nuclear stain and 
YAP/TAZ signal could be distinguished at the magnification used for imaging spheroids.  
This provided promising results for the feasibility of staining a larger spheroid structure.   
For the CellProfiler analysis, we found the maximum intensity projection of the z 
stack of the images containing the YAP/TAZ and DAPI stained cells.  Because the cells 
were sparsely seeded within the gel, there was no overlap of cells in the z direction.  This 
indicated that the maximum intensity z projection only contained the cell of interest.  The 
nuclei and YAP/TAZ signal were reliably segmented using the custom pipeline (Figure 
5-14 and Figure 5-15).  Individual nuclei of touching cells were also discerned and 
segmented.  Based on the promising results of staining single cells in 3D, we moved to 
staining our 3D embedded spheroids in 2 mg/mL and 4 mg/mL collagen.  
 
5.3.5 YAP/TAZ expression in spheroids  
 To study YAP/TAZ activity in our 3D spheroid model, we embedded MDA-MB-
231 and MCF10A spheroids in 2 mg/mL and 4 mg/mL collagen and CUBIC cleared the 
samples for 6 days.  Due to the larger size of the spheroid, the staining time was adjusted 
from the 3D single cell model to ensure proper diffusion of the stains and reagents 
throughout the sample.  MDA-MB-231 and MCF10A spheroids in 2 mg/mL and 4 
mg/mL collagen at Day 0 stained with YAP/TAZ antibody and nuclear stain are shown in 
Figure 5-17 and 5-18, respectively.  The MDA-MB-231 spheroids in 2 mg/mL and 4 
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mg/mL fixed at Day 2 are shown in Figure 5-18.  
 To analyze the YAP/TAZ activity within our spheroids, we quantified the amount 
of nuclear and cytoplasmic YAP/TAZ within the core and edge region of the 2D middle 
z-slice.  The middle section of the spheroid provided information about the spheroid core 
in addition to the spheroid edge.  Using ImarisColoc, we determined the colocalization of 
the YAP/TAZ and DAPI signal within the nuclear region.  The nuclear to cytosolic 
YAP/TAZ ratio was calculated for each region and cell type (Figure 5-22).   
 The nuclear to cytosolic YAP/TAZ ratio was lower in 2 mg/mL for both cell 
types, indicating that there is more cytoplasmic YAP/TAZ in these conditions.  In 
addition, the YAP/TAZ ratio was lower in the core region compared to the edge region.  
The MCF10A cells were found to have a lower YAP/TAZ ratio than the MDA-MB-231 
cells in both regions and collagen concentrations.  The MDA-MB-231 spheroid core and 
edge regions in 4 mg/mL had the highest YAP/TAZ ratios.  
  
 
5.4 Discussion  
 The goal of this chapter was to develop a method to investigate the relationship 
between the 3D microenvironment and YAP/TAZ activity.  By integrating tissue clearing 
with our 3D embedded spheroid model, we were able to visualize YAP/TAZ activity 
throughout a dense spheroid within a collagen matrix.  YAP/TAZ activity is commonly 
studied using a 2D model with cells on glass or polyacrylamide substrates.  However, the 
altered cytoskeletal configuration and lack of cell-ECM interactions may not provide 
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results that translate to in vivo101.  
 With the integration of CUBIC clearing with our 3D embedded spheroid model, 
we were able to fully image 1000 and 10,000 cell spheroids.  Only the outer layers of the 
uncleared spheroids could be imaged with none of the interior core cells visible.  In 
comparison, the cleared spheroid could be imaged with distinct nuclei clearly visible in 
the middle of the spheroid.  Light diffusion was determined as the limiting factor for deep 
image penetration by comparing cleared and uncleared spheroids formed with LifeAct 
GFP MDA-MB-231 cells.  Because we still could not image the center of the uncleared 
spheroid, stain diffusion as a limiting factor for imaging depth could be eliminated.   
 In addition, we were able to study the dynamics of cancer progression by 
acquiring discrete temporal snapshots of spheroid invasion.  By fixing the spheroid at 
distinct time points, we could characterize changes to the spheroid structure and invasion 
of the cells into the matrix.  Using a spheroid size that fit into the microscope field of 
view, we could simultaneously image cells that had migrated into the matrix in addition 
to the spheroid itself.  We fixed spheroids at day 0, day 1, and day 2, but any time 
increments and length could be studied.  For example, if we wanted to characterize early 
invasion dynamics, we could fix the samples every 4 hours for 24 hours.  By integrating 
these methods, we developed a system that allows for visualization of entire spheroid 
structures and invasion dynamics.   
 With the spheroid nuclei volume analysis, we found that the MDA-MB-231 
spheroids had higher nuclei volume than the MCF10A spheroids.  MCF10A cells are an 
epithelial cell line, indicating that they have a high cadherin content and stronger cell-cell 
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adhesions compared to the mesenchymal MDA-MB-231 cells181.  As a result, the 
MCF10A cells may form more compact spheroid structures, which could lead to smaller 
nuclei volume due to limitation of physical space.  We also found that the nuclei volumes 
for both cell types in the 2 mg/mL condition were higher than that of the 4 mg/mL 
condition for all three regions.  Higher collagen concentration is associated with 
increased collagen fibrils, higher density, and smaller pore size182.  As a result, the 
structure of the 4 mg/mL collagen concentration matrix may cause the cells to be more 
physically confined and have smaller nuclei volumes.   
 YAP/TAZ activity within the core and edge regions of the spheroid was found to 
be mostly cytoplasmic for both MDA-MB-231 and MCF10A spheroids in 2 mg/mL and 
4 mg/mL collagen.  The lower stiffness of the collagen matrix compared to a glass 
substrate and the high cell density may lead to mostly cytoplasmic YAP/TAZ activity.  
We previously found that cells seeded sparsely in 2D on glass, 1kPa, and 24kPa 
polyacrylamide substrates had higher nuclear YAP/TAZ.  The YAP/TAZ nuclear fraction 
was found to increase as substrate stiffness increased and decrease as cell seeding density 
increased.  Contact inhibition of YAP/TAZ activity was observed for confluent and 
densely seeded cells.  Consequently, the YAP/TAZ ratio in the dense spheroids 
embedded in comparatively low substrate stiffness was non-nuclear.  The higher 
YAP/TAZ ratio in the 4 mg/mL spheroids compared to the 2 mg/mL spheroids could be 
due to the relatively higher stiffness of the matrix, which may indicate that contact 
inhibition is also affected by ECM mechanosensing in 3D.   
 Because the YAP/TAZ pathway is influenced by ECM mechanosensing and cell-
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cell contacts, a physiologically relevant 3D model must be utilized.  With our system that 
integrates tissue clearing with an embedded 3D in vitro model, we can characterize the 
nuclei volume and YAP/TAZ activity throughout a dense spheroid structure.  In addition, 
we can characterize the spheroid behavior temporally using our discrete invading 
spheroid model.  Therefore, investigating how tumor progression, cell type, and ECM 
concentration influence YAP/TAZ activity may lead to more targeted treatment strategies 
to reduce metastasis and chemoresistance. 
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Figure 5-1: Interaction of ECM and the YAP/TAZ Pathway  
Schematic showing an overview of factors studied in this section (circled in blue).  The 
relationship between the mechanical effects of the ECM and YAP/TAZ activity within a 
3D matrix was investigated.  
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Figure 5-2: Spheroid Clearing Procedure 
The spheroid is formed, embedded into collagen, fixed in PFA, and completely immersed 
in reagent-1.  After 5 to 7 days of clearing with reagent-1, the sample is imaged using a 
multi-photon microscope. 
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Figure 5-3: Cleared and Uncleared 10K MDA Spheroid Over 48 Hours 
a-c) Uncleared spheroid embedded in a 2 mg/mL collagen gel imaged at 0, 24, and 48 
hours. d-f) Cleared spheroid embedded in a 2 mg/mL collagen gel imaged at 0, 24, and 
48 hours. Scale bar is 200 µm 
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Figure 5-4: Collagen Gel of Cleared and Uncleared Samples 
a) 2 mg/mL collagen gels in a 24 glass bottom well plate at 0 hours of CUBIC clearing. 
b) Identical 2 mg/mL collagen gels after 48 hours of CUBIC clearing.   
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Figure 5-5: Comparison of Cleared and Uncleared 10K MDA spheroid  
a) Uncleared 10,000 cell MDA spheroid embedded within a 2 mg/mL collagen gel b) 
Cleared 10,000 cell MDA-MB-231 spheroid within a 2 mg/mL collagen gel. Both images 
are at the same middle slice position. Scale bar is 200 µm 
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Figure 5-6: MDA-MB-231 LifeAct GFP Spheroid Clearing Comparison  
a) 10,000 cell MDA-MB-231 LifeAct GFP uncleared spheroid b) 10,000 cell MDA-MB-
231 LifeAct GFP cleared spheroid. Both images are at the same middle z-slice position. 
Image taken on scanning confocal microscope with a 20x objective.  
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Figure 5-7: Invading Tumor Spheroid Model  
Schematic of invading tumor spheroid model. Spheroid embedded in collagen gel and 
fixed immediately (0 hour). Spheroid embedded in collagen gel and incubated for 24 
hours before fixing.  Spheroid embedded in collagen gel and incubated for 48 hours 
before fixing.   
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Figure 5-8: MDA-MB-231 1,000 Cell Spheroid Invasion into 2 mg/mL Collagen  
a) 1,000 cell spheroid embedded in 2 mg/mL collagen fixed at 0 hour b) 1,000 cell 
spheroid embedded in 2 mg/mL collagen fixed after 24 hours c) 1,000 cell spheroid 
embedded in 2 mg/mL collagen fixed after 48 hours. Scale bar is 100 µm   
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Figure 5-9: Regions within 3D Spheroid and Center Reference Point  
The schematic shows the core, middle, and edge regions in the 3D spheroid.  The region 
color code is shown in the box to the right.  The purple circles are representative cells in 
the core and edge region.  The yellow lines indicate the distance from the cell to the 
center reference point (black circle).  
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Figure 5-10: 3D Segmented Nuclei of MDA-MB-231 Spheroid at Day 0 in 2 mg/mL 
collagen 
3D segmented nuclei of MDA-MB-231 spheroid at Day 0 in 2 mg/mL collagen viewed in 
Imaris following the Cell module analysis 
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Figure 5-11: Comparison of Nuclei Volume of MDA-MB-231 and MCF10A 
Spheroids at Day 0 
Comparison of the core, middle, and edge nuclei volumes for the MDA-MB-231 and 
MCF10A spheroids embedded and fixed at Day 0. P value determined using ANOVA 
with Tukey-Kramer post hoc analysis (*P < 0.01). Error bars are s.e.m. 
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Figure 5-12: Nuclei Volume Day 0 and Day 2 MDA-MB-231 Spheroid Comparison  
Comparison of the MDA-MB-231 spheroid nuclei volume at Day 0 and Day 2 in 2 
mg/mL and 4 mg/mL collagen.  Error bars are s.e.m. P value determined using ANOVA 
with Tukey-Kramer post hoc analysis (*P < 0.01).   
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Table 5-1: Antibody Immunofluorescence Staining Information  
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Figure 5-13: MDA-MB-231 Single Cells Embedded in 2 mg/mL and 4 mg/mL 
Collagen with YAP/TAZ Stain  
MDA-MB-231 single cells embedded in 2 mg/mL collagen with a) YAP/TAZ stain b) 
DAPI nuclear stain, and c) merged view.  MDA-MB-231 single cells embedded in 4 
mg/mL collagen with d) YAP/TAZ stain e) DAPI nuclear stain, and f) merged view.  
Scale bar is 10 µm 
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Figure 5-14: Identification of Nuclei using Cell Profiler 
a) Nuclei of MDA-MB-231 single cells embedded in 2 mg/mL collagen with DAPI stain 
b) Identification of nuclei with Identify Primary Objects pipeline c) Segmented nuclei 
indicated by distinct colors 
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Figure 5-15: YAP/TAZ Identification and Segmentation 
a,c) Original YAP/TAZ stained image of single cells embedded in 2 mg/mL collagen b) 
YAP/TAZ signal found in the nucleus determined using the previously segmented nuclei 
as a mask d) YAP/TAZ signal found in the cytoplasm determined using the previously 
segmented nuclei as an inverted mask 
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Figure 5-16: MDA-MB-231 1000 Cell Spheroid Embedded in 2 mg/mL and 4 
mg/mL collagen at Day 0 
MDA-MB-231 1000 cell spheroid embedded in 2 mg/mL with a) YAP/TAZ stain b) 
DAPI nuclear stain and c) merged signal. MDA-MB-231 1000 cell spheroid embedded in 
4 mg/mL with a) YAP/TAZ stain b) DAPI nuclear stain and c) merged signal. Image 
shown is the middle z slice position of the 3D acquisition. Scale bar is 100 µm 
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Figure 5-17: MCF10A 1000 Cell Spheroid Embedded in 2 mg/mL and 4 mg/mL 
collagen at Day 0 
MCF10A 1000 cell spheroid embedded in 2 mg/mL with a) YAP/TAZ stain b) DAPI 
nuclear stain and c) merged signal. MCF10A 1000 cell spheroid embedded in 4 mg/mL 
with a) YAP/TAZ stain b) DAPI nuclear stain and c) merged signal. Image shown is the 
middle z slice position of the 3D acquisition. Scale bar is 100 µm 
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Figure 5-18: MDA-MB-231 1000 Cell Spheroid Embedded in 2 mg/mL and 4 
mg/mL collagen at Day 2 
MDA-MB-231 1000 cell spheroid embedded in 2 mg/mL with a) YAP/TAZ stain b) 
DAPI nuclear stain and c) merged signal at Day 2. MDA-MB-231 1000 cell spheroid 
embedded in 4 mg/mL with a) YAP/TAZ stain b) DAPI nuclear stain and c) merged 
signal at Day 2. Image shown is the middle z slice position of the 3D acquisition. Scale 
bar is 100 µm. 
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Figure 5-19: MCF10A and MDA-MB-231 Spheroid Secondary Stain Control  
MCF10A 1000 cell spheroid embedded in 2 mg/mL collagen at day 2 with a) DAPI 
nuclear stain and b) only secondary antibody stain (no primary antibody) to test for 
nonspecific binding. MDA-MB-231 1000 cell spheroid embedded in 4 mg/mL collagen 
at day 2 with c) DAPI nuclear stain and d) only secondary stain to test for nonspecific 
binding. Scale bar is 100 µm.  
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Figure 5-20: MCF10A Day 0 Spheroid Edge and Core Regions  
a) Edge with core region removed and b) core with edge region removed of MCF10A 
1000 cell spheroid in 4 mg/mL at day 0   
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Figure 5-21:  Colocalized Regions of MDA-MB-231 Spheroid in 2 mg/mL Collagen 
at Day 0 
MDA-MB-231 spheroid core a) YAP/TAZ and DAPI stain composite image b) 
colocalized regions. MDA-MB-231 spheroid edge c) YAP/TAZ and DAPI stain 
composite image d) colocalized regions. 
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Figure 5-22:  Nuclear to Cytosolic YAP/TAZ Ratio of MDA-MB-231 and MCF10A 
Spheroids in 2 mg/mL and 4 mg/mL collagen 
The nuclear to cytosolic YAP/TAZ ratio of the spheroid core and edge were quantified 
for Day 0 MDA-MB-231 and MCF10A spheroids in 2 mg/mL and 4 mg/mL collagen.   
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CHAPTER 6. Conclusions and Future Directions 
 
 
6.1 Summary and Conclusions  
 The overall motivation for this work was to understand the impact of the tumor 
microenvironment on the intracellular properties within a 3D ECM.  In this dissertation, 
we address this goal through three questions.   
 In Chapter 3, we established a 3D experimental model for quantifying and 
studying drug response in vitro.  In addition to determining the drug response in 3D, we 
were able to vary the cell type, drug incubation time, and collagen concentration to 
recapitulate more physiologically relevant conditions.  With this system, we can more 
effectively determine the drug response compared to the conventional 2D in vitro drug 
studies.  We quantified the drug response within a 2D monolayer and 3D diffuse single 
cell model with varying parameters.  The IC50 for cells in 3D was found to be higher 
than for those in 2D, indicating that more drug was required to kill 50% of the cells.  In 
addition, we found that a longer drug incubation time resulted in a lower IC50.  
Furthermore, the cancerous MDA-MB-231 cells were found to have higher IC50 values 
than the non-cancerous MCF10A cells.  The findings from this chapter highlight the need 
to incorporate varying matrix stiffness, drug incubation time, and cell type into drug 
studies.  
 In Chapter 4, we characterized the relationship between the mechanical 
components of the matrix and intracellular activity using particle-tracking microrheology.  
The intracellular motor activity and stiffness of non-cancerous and cancerous breast cells 
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and spheroids embedded within 3D collagen matrices were determined.  In addition, we 
were able to analyze how drug treatment affects the intracellular behavior of cells within 
a physiologically relevant environment.  The intracellular MSD of untreated cells was 
found to increase with decreasing collagen concentration.  The drug treated cells were 
also found to have altered stiffness and motor driven activity dependent on the collagen 
concentration.  The MCF10A cells were found to have lower stiffness and intracellular 
activity compared to the MDA-MB-231 cells.  The spheroid core cells were also found to 
have lower stiffness and intracellular activity for both cell types.  The results from this 
chapter indicate the impact of the 3D microenvironment on the intracellular activity of 
cells and thus the need to incorporate physiologically relevant microenvironments into 
cancer research.  
 Finally, in Chapter 5 we integrated our 3D spheroid model with tissue clearing to 
investigate spheroid morphology and YAP/TAZ activity within a physiologically relevant 
environment.  Using this integrated system, the entire spheroid structure and discrete 
invasion dynamics of cells migrating into the matrix could be imaged.  In addition, the 
spatial and temporal heterogeneity of the spheroid nuclei volumes were quantified.  The 
MDA-MB-231 and MCF10A spheroid nuclei volumes in 2 mg/mL collagen were found 
to be larger than the nuclei volumes in 4 mg/mL collagen.  The spheroid nuclei volume 
also decreased in Day 2 conditions compared to those of the Day 0 condition for both 2 
mg/mL and 4 mg/mL conditions.  YAP/TAZ activity was quantified in the core and edge 
regions for MDA-MB-231 and MCF10A spheroids in 2 mg/mL and 4 mg/mL collagen.  
The nuclear to cytosolic YAP/TAZ ratio was found to be lower in 2 mg/mL and in the 
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core region, indicating that there is more cytoplasmic YAP/TAZ in these conditions.  The 
results from this work demonstrates the heterogeneity of nuclei volume and YAP/TAZ 
activity within a spheroid and their dependence on collagen concentration, spatial 
location, and invasion state.   
 
 
6.2 Future Directions 
 Future directions for the work in Chapter 3 could involve incorporating primary 
cells taken from patients into the 3D in vitro model.  The experiments in Chapter 3 
utilized immortalized breast cell lines from a manufacturer.   However, any cell type can 
be incorporated into the matrix in order to determine drug response.  By using the 
patient’s cells, optimal drug type or combination of drugs and dosage can be determined 
prior to administering to the patient.   
 In addition, the matrix stiffness can be adjusted to match the disease type and 
stage of the patient.  For example, if the patient has dense breast tissue, the matrix of the 
in vitro model can be adjusted to match.  By using the patient’s cells and physiologically 
relevant matrix values, the appropriate drug regime can be determined without harming 
the patient.  
 Furthermore, the most effective dosing schedule can be determined with this 
system.  Studies have shown that the chemotherapy treatment cycle can put a selective 
pressure on cancer cells and select for resistant cells that repopulate to tumor45,183.  To 
prevent the emergence of cancer stem cells, various dosing schedules or drug 
combinations can be tested to eliminate the possibility of repopulation of the tumor with 
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cancer stem cells. With the ability to modify the type of drug, cell, matrix, and dosing 
schedule, this 3D in vitro system could be used in the clinical setting to lead to improved 
treatment strategies and better patient outcomes.  
 
 The 3D in vitro model integrated with particle-tracking microrheology described 
in Chapter 4 is a platform that can be used to investigate several questions related to 
mechanotransduction and the influence of matrix mechanics in 3D.  Future directions 
could involve investigation of the metabolic activity of the cells.  Changes in the 
metabolic activity of cells in different collagen concentrations and with different drug 
treatments would provide another metric to measure the impact of matrix mechanics on 
the cell.  NADH and FAD fluorescence are an endogenous signal that indicate the 
metabolic activity of cells and can be measured with a multi-photon184. However, an 
incubation chamber would be required to maintain the optimal cellular conditions 
throughout the measurement process.  Quantification of the intracellular and metabolic 
activity of the cells would allow us to better understand the impact of the 3D matrix on 
cellular behavior.  
Future work could also incorporate culturing multiple tumor associated cells types 
together within the spheroid model.  For example, stromal cells, such as fibroblasts and 
endothelial cells, could be added into the multicellular spheroid since these cells have 
been shown to promote tumor progression185.  The combination of cancer and stromal 
cells could provide insight into the intracellular and mechanical changes that occur with 
cancer progression in an even more physiologically relevant system.  
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 In addition, patient’s primary cells and analogous tumor stroma stiffness could 
also be incorporated into the model to understand which drug treatments are the most 
effective based on measurements of stiffness and intracellular activity.  Cancer is very 
heterogeneous and even the same type of cancer can vary from patient to patient.  The 
ECM concentration in the cancer microenvironment can also vary significantly for 
different patients.  Because the ECM concentration has been shown to correlate with 
disease state and prognosis, utilizing the appropriate concentration may lead to improved 
treatment strategies for the corresponding patients.  
 
The 3D spheroid model integrated with tissue clearing is a physiologically 
relevant system that can be used to study the influence of the 3D environment on various 
aspects of cellular activity and structure.  Future work for Chapter 5 could include 
incorporating fluorescent staining of the actin, tubulin, cytoplasm, or other cellular 
components to further understand the cellular architecture throughout the spheroid.  This 
would provide a further characterization of how the cell-cell and cell-ECM interactions 
affect the mechanical structure of cells.  Staining of the cytoplasm would help to increase 
the segmentation accuracy of the cell volume.  Serial sectioning of the spheroid could 
also be performed to physically visualize the interior structure of the spheroid and 
compare to our 3D imaging.     
In addition, different signaling pathways associated with cancer progression can 
be investigated within our 3D embedded spheroid model.  For example, the transforming 
growth factor β (TGF-β) signaling pathway has been shown to be associated with tumor 
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development186.  Increased levels of TGF-β are associated with malignancy and 
metastasis in late stage tumors, but anti-tumor activities, such as cell cycle arrest and 
apoptosis, in early-stage tumors187.  TGF-β has also been shown to influence tumor-
stroma interactions and remodeling of the tumor microenvironment188.  With our cleared 
embedded multicellular spheroid model with discrete invasion dynamics capability, both 
the time and ECM dependent behavior of TGF-β can be studied in a 3D matrix.  
Furthermore, the system can be utilized to investigate combinations of potential 
drug candidates for improved therapy.  For example, the system could be used to identify 
inhibitors that effectively regulate YAP/TAZ activity at different stages of cancer 
progression by accordingly adjusting the matrix stiffness and invasion stage.  Because we 
can visualize the spheroid at a cellular resolution, we can obtain a detailed view of how 
drugs affect the YAP/TAZ activity both spatially and temporally.  With this approach, we 
can develop more effective treatment strategies specific to the patient’s cancer stage to 
further improve patient outcomes. 
Future directions for this work could include further investigating the relationship 
between the YAP/TAZ pathway and the collagen matrix. In aim 3, we studied how 
varying the collagen concentration affected YAP/TAZ activity in different spheroid 
regions and cell types.  To further characterize how the interaction of the cells with the 
matrix influences YAP/TAZ activity, we could use a matrix metalloproteinase (MMP) 
inhibitor such as GM6001 to prevent the cells from degrading or migrating through the 
matrix.  Migration of cells through the ECM is dependent on MMPs, which allow for 
collagen cleavage and ECM remodeling.  With this inhibition, we can study how the cells 
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respond to the fixed matrix concentration and stiffness by measuring the YAP/TAZ 
activity.   
We can also investigate how YAP/TAZ activity affects the remodeling of the collagen 
matrix by activating and deactivating YAP/TAZ.  To deactivate YAP/TAZ, we can use 
siRNA against YAP and TAZ and determine how the matrix is remodeled. We can also 
use YAP/TAZ inhibitors such as dasatinib, statins, and pazopanib, which have been 
found to inhibit the nuclear localization and target gene expression of YAP and YAZ189. 
To activate YAP/TAZ, we can overexpress constitutively active YAP by transfecting 
cells with a commercially available plasmid. Western blot analysis will be performed to 
check that YAP/TAZ protein levels have been increased.  Using multi photon 
microscopy, we are able to image the collagen matrix and visualize individual collagen 
fibers.  Previous work done in our lab has developed a program to quantify the alignment 
of collagen fibers190.  With this program, we can compare the matrix in the normal 
untreated condition, the GM6001 treated, and the YAP/TAZ activated/inactivated 
conditions to determine the relationship of matrix remodeling and YAP/TAZ activity. 
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